Protea Biosciences 10-Q 19 May 17 2017 Q1 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	3 Months Ended
	Mar. 31, 2017	May 18, 2017
Document Information [Line Items]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Mar. 31, 2017
Document Fiscal Year Focus	2,017
Document Fiscal Period Focus	Q1
Entity Registrant Name	Protea Biosciences Group, Inc.
Entity Central Index Key	1,335,103
Current Fiscal Year End Date	--12-31
Entity Filer Category	Smaller Reporting Company
Trading Symbol	PRGB
Entity Common Stock, Shares Outstanding		215,148,532

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($)	Mar. 31, 2017	Dec. 31, 2016
Current assets
Cash and cash equivalents	$ 15,532	$ 78,720
Accounts receivable, less allowance for doubtful accounts of $1,200 and $7,000 as of March 31, 2017 and December 31, 2016, respectively	88,791	436,933
Inventory	40,618	92,244
Prepaid expenses	150,735	121,027
Total current assets	295,676	728,924
Property and equipment, net	2,338,801	2,466,125
Deposits and other noncurrent assets	19,041	19,041
Total Assets	2,653,518	3,214,090
Current Liabilities:
Current maturities on short and long-term debt, net of discount	3,798,276	4,012,149
Accounts payable	1,712,272	1,796,416
Bank line of credit	3,000,000	3,000,000
Obligations to stockholders, net of discount	1,191,386	3,087,956
Derivative liabilities	6,924,124	3,097,921
Other current liabilities	617,518	556,047
Total current liabilities	17,243,576	15,550,489
Long-term debt, net of current maturities	1,834,251	1,769,355
Stockholders’ Deficit
Preferred stock ($0.0001 par value; 10,000,000 shares authorized; none issued or outstanding as of March 31, 2017 and December 31, 2016)	0	0
Common stock ($0.0001 par value; 500,000,000 shares authorized; 209,848,532 and 162,471,373 shares issued and outstanding as of March 31, 2017 and December 31, 2016, respectively)	20,985	16,247
Additional paid-in capital	84,664,764	81,123,483
Accumulated deficit	(101,110,159)	(95,245,530)
Accumulated other comprehensive income	101	46
Total Stockholders’ Deficit	(16,424,309)	(14,105,754)
Total Liabilities and Stockholders’ Deficit	$ 2,653,518	$ 3,214,090

Consolidated Balance Sheets _Pa

Consolidated Balance Sheets [Parenthetical] - USD ($)	Mar. 31, 2017	Dec. 31, 2016
Allowance for Doubtful Accounts Receivable, Current	$ 1,200	$ 7,000
Preferred stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Preferred stock, shares authorized	10,000,000	10,000,000
Preferred Stock, Shares Issued	0	0
Preferred Stock, Shares Outstanding	0	0
Common stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Common stock, shares authorized	500,000,000	500,000,000
Common stock, shares issued	209,848,532	162,471,373
Common stock, shares outstanding	209,848,532	162,471,373

Consolidated Statements of Oper

Consolidated Statements of Operations and Comprehensive Loss - USD ($)	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Gross revenue	$ 354,836	$ 475,338
Cost of revenue	(287,396)	(204,375)
Gross profit	67,440	270,963
Selling, general and administrative expenses	(1,497,306)	(1,604,404)
Research and development expense	(128,940)	(232,610)
Loss from operations	(1,558,806)	(1,566,051)
Other income (expense)
Gains from sales of investment	0	637,100
Gain (loss) on disposal of assets	(15,387)	(182)
Interest expense	(460,318)	(150,329)
Debt conversion inducement cost	(5,000)	0
Change in fair value of derivative liabilities	(3,826,203)	(7,468)
Other income (expense)	1,085	1,386
Total other income (expense)	(4,305,823)	480,507
Loss before income taxes	(5,864,629)	(1,085,544)
Provision for income taxes	0	0
Net loss	(5,864,629)	(1,085,544)
Foreign currency translation adjustment	55	48
Total comprehensive loss	$ (5,864,574)	$ (1,085,496)
Weighted average number of shares of Common stock outstanding - basic and diluted (in shares)	168,961,931	133,299,471
Net loss per share - basic and diluted (in dollars per share)	$ (0.03)	$ (0.01)

Consolidated Statements of Stoc

Consolidated Statements of Stockholders' Deficit - 3 months ended Mar. 31, 2017 - USD ($)	Total	Preferred Stock [Member]	Common Stock [Member]		Additional Paid-in Capital [Member]	Accumulated Deficit [Member]	Accumulated Other Comprehensive Income (Loss) [Member]
Balance at Dec. 31, 2016	$ (14,105,754)	$ 0	$ 16,247		$ 81,123,483	$ (95,245,530)	$ 46
Balance (in shares) at Dec. 31, 2016		0	162,471,373
Issuance of common stock, net issuance costs	$ 563,508	$ 0	$ 917		562,591	0	0
Issuance of common stock, net issuance costs (in shares)	9,173,332	0	9,173,330
Issuance of stock for services	$ 230,000	$ 0	$ 342		229,658	0	0
Issuance of stock for services (in shares)		0	3,416,667
Issuance of stock upon conversion of related party debt	2,609,037	$ 0	$ 3,479		2,605,558	0	0
Issuance of stock upon conversion of related party debt (in shares)		0	34,787,162
Stock-based compensation	41,207	$ 0	$ 0		41,207	0	0
Stock warrants issued for services and debt	102,267	0	0		102,267	0	0
Stock warrants issued as part of debt conversion inducement cost	0	0	0		0	0	0
Net loss	(5,864,629)	0	0		0	(5,864,629)	0
Foreign currency translation adj.	55	0	0		0	0	55
Balance at Mar. 31, 2017	$ (16,424,309)	$ 0	$ 20,985		$ 84,664,764	$ (101,110,159)	$ 101
Balance (in shares) at Mar. 31, 2017		0	209,848,532	[1]
[1]	Includes 21,214,642 shares that contain an anti-dilution provision

Consolidated Statements of Sto6

Consolidated Statements of Stockholders' Deficit [Parenthetical]	3 Months Ended
	Mar. 31, 2017USD ($)$ / shares
Common Stock, Par or Stated Value Per Share	$ 0.0001
Preferred Stock, Par or Stated Value Per Share	0.0001
Preferred Stock [Member]
Preferred Stock, Par or Stated Value Per Share	0.0001
Common Stock [Member]
Common Stock, Par or Stated Value Per Share	$ 0.0001
Issuance Cost | $	$ 124,492

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($)	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Cash flows from operating activities:
Net loss	$ (5,864,629)	$ (1,085,544)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	157,345	158,993
Stock-based compensation	41,207	63,800
Issuance of common stock and warrants for services	332,267	38,445
Issuance of common stock for accrued interest	0	0
Accretion of original issue discount on short-term convertible notes	14,785	27,618
Accretion of debt issue costs on short-term convertible notes	228,790	0
Issuance of common stock with convertible debt	0	27,174
(Gain) loss on disposal of assets	42,933	182
Gains from sales of investment	0	(637,100)
Change in fair value of derivative liabilities	3,826,203	7,468
Net changes in certain assets and liabilities:
Accounts receivable	348,142	(122,639)
Prepaid expenses	(29,708)	55,111
Inventory	(1,437)	44,648
Other noncurrent assets	0	0
Accounts payable	(84,146)	(59,862)
Other current liabilities	153,790	185,201
Net cash used in operating activities	(834,458)	(1,296,505)
Cash flows from investing activities:
Purchase of and deposits on equipment	(19,890)	0
Proceeds from sale of equipment	0	25
Proceeds from sale of investment	0	637,100
Net cash (used in) provided by investing activities	(19,890)	637,125
Cash flows from financing activities:
Proceeds from advances from stockholders	537,148	109,500
Payments on advances from stockholders	0	(57,500)
Proceeds from issuances of debt	0	500,000
Payments of debt issuance costs	0	(60,000)
Payments on debt	(200,000)	(7,783)
Payments on capital leases	(109,551)	(95,996)
Bank Overdraft	0	264,661
Proceeds from sale of common stock	563,508	0
Net cash provided by financing activities	791,105	652,882
Effect of exchange rate changes on cash	55	48
Net decrease in cash	(63,188)	(6,450)
Cash, beginning of period	78,720	6,450
Cash, end of period	$ 15,532	$ 0

Description of Business and Bas

Description of Business and Basis of Presentation	3 Months Ended
	Mar. 31, 2017
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Nature of Operations [Text Block]	1. Description of Business and Basis of Presentation The Company Protea Biosciences Group, Inc. (referred to herein as “Protea,” “the Company,” “we,” “us” and “our”) is an emerging growth, molecular information company that has developed a revolutionary platform technology that enables the direct analysis, mapping and display of biologically active molecules in living cells and tissue samples. The technology platform offers new, unprecedented capabilities useful to the pharmaceutical, diagnostic, clinical research, agricultural and life science industries. “Molecular information” refers to the generation and bioinformatic processing of very large data sets, known as “big data,” obtained by applying the Company’s technology to identify and characterize the proteins, metabolites, lipids and other molecules which are the biologically active molecular products of all living cells and life forms. Our technology is used to improve pharmaceutical development and life science research productivity and outcomes, and to extend and add value to other technologies that are used in research and development, such as three-dimensional tissue models, biomarker discovery, synthetic biologicals and mass spectrometry. In particular, the Company believes that its ability to rapidly provide comprehensive molecular image-based datasets addresses a universal need of the pharmaceutical, diagnostic and clinical research and life science industries. The Company’s commercial development is centered on three lines of business: · Molecular information services – We believe that we are the commercial leader in providing multi-modal Mass Spectrometry Imaging (“MSI”), combining Laser Ablation Electrospray Ionization (“LAESI®”), Matrix Assisted Laser Desorption Ionization (“MALDI”) and optical microscopy. Our proprietary services enable the identification and quantitation of both small molecules (e.g., lipids and metabolites) and large molecules (e.g., proteins) and our services portfolio, inclusive of MSI, proteomics, metabolomics, lipidomics and bioinformatics is unique in the industry. Our clients include major pharmaceutical, chemical and biotechnology companies; · LAESI® instrument platform – We offer our proprietary LAESI® DP-1000 instrument, software and bioanalytical consumables to corporate and academic research laboratories, and; · Molecular diagnostics and clinical research – We apply our multi-modal MSI technologies and workflows in partnership with top-tier medical research institutions to co-develop new molecular diagnostic tests that the company believes can be used to improve the diagnosis and prognosis of cancer and provide requisite information useful in predicting the outcome of cancer treatment. Our current test development programs target the differential diagnosis and prognosis of malignant melanoma and the molecular profiling of subpopulations of cells in lung adenocarcinoma. Basis of Presentation The unaudited Consolidated Financial Statements include the accounts of Protea Biosciences Group, Inc. and its wholly-owned subsidiary, Protea Biosciences, Inc. In the opinion of management, these statements have been prepared on a basis consistent with the December 31, 2016 audited Consolidated Financial Statements and include all material adjustments, consisting of normal recurring adjustments and the elimination of material intercompany transactions and balances, necessary for a fair presentation of the Company’s consolidated financial position and results of operations for the interim periods presented. These unaudited, interim, Consolidated Financial Statements have been prepared pursuant to the rules and regulations of the U.S. Securities and Exchange Commission (“SEC”). Accordingly, they do not include certain information and footnotes normally required by accounting principles generally accepted in the United States of America (“GAAP”) for complete consolidated financial statements. The consolidated results of operations for the three months ended March 31, 2017 are not necessarily indicative of the results of operations for the full fiscal year. These Consolidated Financial Statements and related footnotes should be read in conjunction with the financial statements and footnotes thereto included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2016 filed with the SEC on April 14, 2017 (“2016 Form 10-K”). Emerging Growth Company The Company is an “emerging growth company” as defined in the Jumpstart Our Business Startups Act of 2012 (“JOBS Act”) and may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies including, but not limited to, not being required to comply with the auditor attestation requirements of Section 404(b) of the Sarbanes-Oxley Act, and exemptions from the requirements of Sections 14A(a) and (b) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), to hold a nonbinding advisory vote of shareholders on executive compensation and any golden parachute payments not previously approved. The Company has elected to use the extended transition period for complying with new or revised accounting standards under Section 102(b)(1) of the JOBS Act. This election allows us to delay the adoption of new or revised accounting standards that have different effective dates for public and private companies until those standards apply to private companies. As a result of this election, our consolidated financial statements may not be comparable to companies that comply with public company effective dates. We will remain an “emerging growth company” for up to five years following our initial public offering, that is, until February 2019, although we will lose that status sooner if our revenues exceed $1 billion, if we issue more than $1 billion in non-convertible debt in a three-year period, or if the market value of our common stock that is held by non-affiliates exceeds $700 million as of any June 30. To the extent that we continue to qualify as a “smaller reporting company,” as such term is defined in Rule 12b-2 under the Exchange Act, after we cease to qualify as an emerging growth company, certain of the exemptions available to us as an emerging growth company may continue to be available to us as a smaller reporting company, including: (1) not being required to comply with the auditor attestation requirements of Section 404(b) of the Sarbanes Oxley Act; (2) scaled executive compensation disclosures, and; (3) the requirement to provide only two years of audited financial statements instead of three years. Critical Accounting Policies Information with respect to the Company’s critical accounting policies which management believes are the most important to the portrayal of the Company’s reported results of operations and financial condition and that require management’s most difficult, subjective or complex judgements, often as the result of the need to make estimates about the effects of matters that are inherently uncertain, is contained in Part II, Item 7 of our 2016 Form 10-K. Recently Issued Accounting Pronouncements There were no changes to the recently issued accounting pronouncements as described in the consolidated financial statements included in our 2016 Form 10-K. As mentioned above, as permitted under the JOBS Act, the Company has elected to delay the adoption of new or revised accounting standards that have different effective dates for public and private companies until those standards apply to private companies. Going Concern The Company’s Consolidated Financial Statements included in this report have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities and commitments in the normal course of business. The Company has funded its activities to date almost exclusively from debt and equity financings as well as sales of certain assets. Substantially all of the Company’s property and equipment are security for outstanding indebtedness. We will continue to require substantial funds to support our molecular information services business and advance global commercialization of our LAESI® instrument platform and service outstanding debt obligations, including scheduled interest and principal payments, and fulfilling payment obligations related to debt that has reached maturity. The Company has experienced negative cash flows from operations since inception. Since inception, our operations have been funded primarily through proceeds received from the issuance of debt and sale of equity securities in private placement offerings and, from time-to-time, sales of certain assets. Management intends to continue to meet the Company’s operating cash flow requirements by raising additional funds from the sale of equity or debt securities, the sale of certain assets, and possibly developing corporate development partnerships to advance our molecular information technology development activities by sharing the costs of development and commercialization. For example, we could also enter into a transaction such as a merger with a business that is complimentary to ours. We have also worked closely with various parties that financed our short- and long-term debt to obtain extensions and modifications that deferred or reduced amounts due under these obligations. Such extensions and modifications have included, in certain cases, the issuance of warrants. In addition, three members of the Company’s Board of Directors and the estate of a former board member guarantee payment of the Company’s outstanding bank line of credit. Such extensions, modifications and guarantees have been an important part of the Company’s ability to manage its liquidity and short-term capital resources. In addition, as part of these efforts, the Company has delayed payments to certain vendors and suppliers. As of March 31, 2017, the Company’s accounts payable balance of $ 1,712,272 1,558,698 1,290,244 1,290,244 1,750,000 The bank line of credit has been presented as a currently liability as the Company was in arrears with its interest at March 31, 2017. The line of credit of $ 3,000,000 As of the date of this report, the Company is in default with all but one short-term convertible notes with the principal amount totaling $ 2,384,222 September 30, 2017 10 In March 2017, the Company’s debt obligation to stockholders decreased $ 2,516,719 34,787,162 69,574,324 In the first quarter of 2017, the Company issued 9,173,332 18,346,662 688,000 We have sold most our investment in AzurRx BioPharma, Inc. (“AzurRx”) as a means of obtaining additional cash in prior periods. As of March 31, 2017, our ownership interest in AzurRx was 1.7 basis. As of the date of this report, the Company holds 125,757 100,000 1.00 25,000 Certain of the Company’s outstanding financial instruments contain anti-dilution provisions that may be triggered by the issuance of Common Stock or financial instruments such as Preferred Stock and warrants that are convertible or otherwise exchangeable for shares of the Company’s Common Stock. As a result of the 2016/17 Offering anti-dilution provisions under certain outstanding financial instruments have been triggered. Under such provisions the Company shall issue 85,724,996 Aside from further issuances of its Common Stock, the Company is exploring other options for obtaining additional financial resources such as the issuances of short-term debentures and Preferred Stock. There can be no assurance that we will be successful in raising enough funds to sustain operations. Since inception, we have been successful in raising funds and selling certain assets to fund our operations and believe that we will be successful in obtaining the necessary capital resources to fund our operations going forward; however, there can be no assurances that we will be able to secure any additional funding or capital resources or the terms and conditions of any such arrangements. These factors raise substantial doubt about our ability to continue as a going-concern. The accompanying Consolidated Financial Statements do not include any adjustment that might be necessary if the Company is unable to continue as a going concern.

Gross Revenue

Gross Revenue	3 Months Ended
	Mar. 31, 2017
Segment Reporting [Abstract]
Segment Reporting Disclosure [Text Block]	2. Gross Revenue Three Months Ended March 31, 2017 2016 Molecular information services $ 257,753 $ 217,052 LAESI® instrument platform 6,883 179,795 Research products 90,200 78,791 Gross revenue $ 354,836 $ 475,338

Derivative Liabilities

Derivative Liabilities	3 Months Ended
	Mar. 31, 2017
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Derivative Instruments and Hedging Activities Disclosure [Text Block]	3. Derivative Liabilities The Company does not use derivative instruments to hedge exposures to cash flow, market or foreign currency risks. However, the Company has certain financial instruments that are embedded derivatives associated with certain capital raises and common stock purchase warrants. The Company evaluates all of its financial instruments to determine if those contracts or any potential embedded components of those contracts qualify as derivatives to be separately accounted for in accordance with FASB Accounting Standards Codification 815-10-05-4 and 815-40. This accounting treatment requires that the carrying amount of any embedded derivatives be recorded at fair value at issuance and marked-to-market at each balance sheet date. If the fair value is recorded as a liability, as is the case with the Company, the change in the fair value during the period is recorded as either income or expense. Upon conversion or exercise, the derivative liability is marked to fair value at the conversion date and then the related fair value is reclassified to equity. See also Note 4 Fair Value of Financial Assets and Liabilities – Derivative Financial Instruments.

Fair Value of Financial Assets

Fair Value of Financial Assets and Liabilities - Derivative Financial Instruments	3 Months Ended
	Mar. 31, 2017
Fair Value Disclosures [Abstract]
Derivatives and Fair Value [Text Block]	4. Fair Value of Financial Assets and Liabilities – Derivative Financial Instruments We measure the fair value of financial assets and liabilities in accordance with GAAP, which defines fair value, establishes a framework for measuring fair value and requires certain disclosures about fair value measurements. GAAP defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. GAAP also establishes the fair value hierarchy, which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. The three levels of inputs used to measure fair value: Level 1 – quoted prices in active markets for identical assets or liabilities Level 2 – quoted prices for similar assets and liabilities in active markets or inputs that are observable Level 3 – inputs that are unobservable (for example, the probability of a capital raise in a “binomial” methodology for valuation of a derivative liability directly related to the issuance of common stock warrants) The Company has entered into certain financial instruments, such as convertible debentures and equity financing arrangements, which include variable conversion rates, include anti-dilution provisions (“down-round protection”) and detachable warrants that are: (i) not afforded equity classification; (ii) embody risks not clearly and closely related to host contracts, or; (iii) may be net-cash settled by the counterparty. Such derivative liabilities are recorded at fair value at the issuance date. Subsequent changes in fair value are recorded through the consolidated statement of comprehensive loss. For the Company, the Level 3 financial liability is the derivative liabilities related to certain Common Stock and warrants that include “down-round protection” that are valued using the “Monte Carlo Simulation” technique. While the majority of inputs are Level 2, this technique necessarily incorporates a capital raise assumption which is unobservable and, therefore, a Level 3 input. Expected life (years) Risk-free rate Volatility Probability of a capital raise Derivative liabilities 0.50 – 5.00 0.91% and 1.27% 81.05 % 100 % Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis The Company’s derivative liabilities are related to certain Common Stock issuances that included “down-round protection”, warrants issued in conjunction with certain Common Stock and debt issuances, including warrants granted to the Placement Agent related to such issuances, that included “down-round protection”, and the variable conversion rate feature of certain short-term convertible debentures. See also Note 12 Debt, Note 13 Common Stock, and Note 15 Warrants. Fair value measurements as of March 31, 2017 Carrying value Level 1 Level 2 Level 3 Derivative liabilities – Common Stock $ 2,581,090 $ – $ – $ 2,581,090 Derivative liabilities – Warrants 3,710,217 – – 3,710,217 Derivative liabilities – Convertible debentures 632,817 – – 632,817 Total $ 6,924,124 $ – $ – $ 6,924,124 Fair value measurements as of December 31, 2016 Carrying value Level 1 Level 2 Level 3 Derivative liabilities – Common Stock $ 2,016,370 $ – $ – $ 2,016,370 Derivative liabilities – Warrants 854,553 – – 854,553 Derivative liabilities – Convertible debentures 226,998 – – 226,998 Total $ 3,097,921 $ – $ – $ 3,097,921 The Company’s assessment of the probability of future capital raises is considered to be high. Such capital raise activities are estimated to take place at levels that could possibly result in anti-dilution triggers—currently at $ 0.075 than $0.09 per As a result of the 2016/17 Offering unit share issuances, anti-dilution provisions under certain outstanding financial instruments have been triggered, which was considered in the assumptions for future capital raise activity at March 31, 2017. Three Months Ended March 31, 2017 Total fair value Derivative liabilities measurements Common Convertible using Level 3 stock Warrants debt inputs Balance as of December 31, 2016 $ 2,016,370 $ 854,553 $ 226,998 $ 3,097,921 Unrealized loss on derivative liabilities outstanding as of December 31, 2016 564,720 1,725,474 – 2,290,194 Fair value of variable conversion rate for convertible debentures issued in 2017 – – 405,819 405,819 Fair value of derivative liabilities associated with other financial instruments issued in 2017 – 1,130,190 – 1,130,190 Balance as of March 31, 2017 $ 2,581,090 $ 3,710,217 $ 632,817 $ 6,924,124

Net Loss per Share

Net Loss per Share	3 Months Ended
	Mar. 31, 2017
Earnings Per Share [Abstract]
Earnings Per Share [Text Block]	5. Net Loss per Share Basic and diluted loss per common share is computed based on the weighted average number of shares of Common Stock outstanding, or 168,999,709 for the three months ended March 31, 2017; for the comparative periods in 2016, weighted average number of shares of Common Stock outstanding was 133,299,471. Common share equivalents (which may consist of stock options, warrants and convertible debt) are excluded from the computation of diluted loss per share for all periods presented because including them would be anti-dilutive. Common share equivalents that could potentially dilute basic earnings per share in the future, and which were excluded from the computation of diluted loss per share, were 278,374,047 and 80,102,519 shares as of March 31, 2017 and March 31, 2016, respectively.

Inventory

Inventory	3 Months Ended
	Mar. 31, 2017
Inventory Disclosure [Abstract]
Inventory Disclosure [Text Block]	Inventory March 31, 2017 December 31, 2016 Finished goods $ 10,307 $ 8,725 Work-in progress 30,311 83,519 Total inventory $ 40,618 $ 92,244

Property and Equipment

Property and Equipment	3 Months Ended
	Mar. 31, 2017
Property, Plant and Equipment [Abstract]
Property, Plant and Equipment Disclosure [Text Block]	7. Property and Equipment Equipment 5 – 10 years Vehicles 5 years Leasehold improvements Life of lease Software 3 years March 31, 2017 December 31, 2016 Lab equipment $ 5,701,039 $ 5,698,009 Computer equipment 552,423 552,423 Office equipment 191,248 191,248 Leasehold improvements 212,730 212,730 6,657,440 6,654,410 Accumulated depreciation (4,318,639) (4,188,285) Property and equipment, net $ 2,338,801 $ 2,466,125 For the three months ended March 31, 2017, depreciation expense was $ 157,345 $158,993

Trade Accounts Receivable and O

Trade Accounts Receivable and Other Noncurrent Assets	3 Months Ended
	Mar. 31, 2017
Investments, All Other Investments [Abstract]
Investments and Other Noncurrent Assets [Text Block]	8. Trade Accounts Receivable and Other Noncurrent Assets Trade accounts receivable, net includes a bad debt allowance of $ 1,200 7,000 Other noncurrent assets consisted of deposits totaling $ 19,041

Bank Line of Credit

Bank Line of Credit	3 Months Ended
	Mar. 31, 2017
Bank Line of Credit [Abstract]
Bank Line of Credit [Text Block]	9. Bank Line of Credit The Company has a line of credit with a bank that is authorized to $ 3,000,000 The interest rate is variable and equal to 0.75% plus prime with a minimum rate of 5.87% per annum. July 12, 2018 3,000,000 The Company’s line of credit with the bank requires the Company to adhere to certain customary covenants. For example, the bank can issue a default notice to the Company and accelerate payment of the outstanding balance if the Company fails to make a scheduled interest payment to the bank, is in default under any agreement with a third party which materially and adversely affects the Company’s property, operations or financial condition, or the Company does not make timely payments on property that is useful its business, including maintenance and repairs of such property. As of the date of this report, the Company is one month in arrears with scheduled payments to the bank. The bank has not issued any notice to the Company regarding any default or possible default under the line of credit; however, this has caused the Company to classify the line of credit as a current liability.

Obligations to Stockholders

Obligations to Stockholders	3 Months Ended
	Mar. 31, 2017
Loan Payable [Abstract]
Loans Payable to Stockholders [Text Block]	10. Obligations to Stockholders During the three months ended March 31, 2017, the Company received advances equal to an aggregate of $ 537,148 3,625,104 During 2014, the Company received advances equal to an aggregate of $ 1,415,000 10 1,415,000 1,415,000 0.80 1,500,000 900,000 101,177 250,000 10,950 165,000 105,078 1,080,312 0.25 540,156 0.50 7,227 31,455 1,000,000 917,000 83,000 In March 2017, certain related parties agreed to convert $ 2,320,400 196,319 92,319 34,787,162 0.075 34,787,162 0.09 34,787,162 0.1125 The $ 200,000 194,556 15,047 On March 14, 2017, the Company received an extension of maturity on the $ 255,000 See Note 13 Common Stock related to the conversion of advances and interest into shares of Common Stock. See also Note 18 Evaluation of Subsequent Events for activity related to advances and other loans payable to stockholders after March 31, 2017.

Other Current Liabilities

Other Current Liabilities	3 Months Ended
	Mar. 31, 2017
Payables and Accruals [Abstract]
Accounts Payable and Accrued Liabilities Disclosure [Text Block]	11. Other Current Liabilities Other current liabilities consist of the following at: March 31, 2017 December 31, 2016 Accrued expenses $ 33,358 $ 68,411 Accrued interest 304,266 264,507 Accrued warranty expense 35,000 45,000 Accrued payroll and benefits 189,322 119,619 Accrued sales tax – 103 Unearned revenue 55,572 58,407 Other payables and accrued expenses $ 617,518 $ 556,047

Debt

Debt	3 Months Ended
	Mar. 31, 2017
Debt Disclosure [Abstract]
Long-term Debt [Text Block]	12. Debt Convertible Promissory Notes with WVJITB The Company has outstanding two convertible promissory notes with the West Virginia Jobs Investment Trust Board (“WVJITB”). One is an 18 290,000 3 400,000 290,000 300,000 On January 17, 2017, the Company and WVJITB entered into another addendum, loan modification, whereby the maturity date of the promissory note was extended until December 31, 2017. The loan modification requires the Company to pay all accrued unpaid interest is due in full on March 1, 2017. Starting in April 2017 principal payments of $ 50,000 5,000 750,000 0.10 As of March 31, 2017, the principal balance of each note has been offset with the fair value of the warrant. The relative fair value of the warrant at the issuance date was estimated at $ 30,825 7,322 Promissory Note with WVDO As of January 31, 2017, the Company was eleven months is arrears on scheduled principal and interest payments on an outstanding note payable to the West Virginia Development Office (“WVDO”). The deferral amount totaled $ 92,873 Convertible Debentures and September 2016 OID Note As of March 31, 2017, the Company is in default under approximately $ 2,250,544 2,384,222 exchange their debentures for a new 20% OID convertible debenture due September 30, 2017, plus one share of our Common Stock for each $1.00 20 100 September 2016 10% OID Secured Promissory Note As of March 31, 2017, the Company is in negotiations with the holder of the note to extend the maturity date. The current balance of the note is $ 280,000 Capital Leases From time to time, in the normal course of business, the Company enters into capital leases to finance equipment. As of March 31, 2017, the Company had six capital lease obligations outstanding with imputed interest rates ranging from 5.04 9.45 1,783,676 See Note 18 Evaluation of Subsequent Events for additional activity and information regarding debt. March 31, 2017 December 31, 2016 1) Note Payable to the WVDO $ 92,873 $ 92,873 2) Note Payable to the WVEDA (a) 143,312 143,312 3) Note Payable to the WVIJDC (b) 139,229 139,229 4) Note Payable to the WVEDA (a) 572,148 572,148 5) Note Payable to the WVIJDC (b) 581,987 581,987 6) Note Payable to the WVJITB 290,000 290,000 7) Note Payable to the WVJITB 300,000 300,000 8) Note Payable to the WVEDA (a) 168,362 168,362 9) Convertible Debenture 2 nd rd 2,114,438 2,114,438 10) September 2016 10% OID Secured Promissory Note 280,000 480,000 11) September 2016 20% OID Note 156,250 156,250 12) Short-term Convertible Note in March 2016 – - 13) Capital leases 818,979 928,530 Total 5,657,578 5,967,129 Less: current portion (3,798,276) (4,012,149) Less: unamortized original issue discount – (22,001) Less: unamortized debt issuance costs (25,051) (163,624) Long-term portion $ 1,834,251 $ 1,769,355 (a) West Virginia Economic Development Authority (b) West Virginia Infrastructure and Jobs Development Council Future required minimum Year Ended December 31: principal payments 2017 $ 3,733,206 2018 534,352 2019 500,357 2020 495,353 2021 and thereafter 394,310 Total $ 5,657,578

Common Stock

Common Stock	3 Months Ended
	Mar. 31, 2017
Equity [Abstract]
Common Stock [Text Block]	13. Common Stock The Company was authorized to issue a total of 510,000,000 500,000,000 0.0001 10,000,000 0.0001 750,000,000 The Company filed the Restated Charter with the Secretary of State of the State of Delaware on April 25, 2017 to increase the Company’s authorized shares to 760,000,000 750,000,000 0.0001 10,000,000 0.0001 Proxy On January 31, 2017, at a special meeting of the Board of Directors, our Board of Directors approved by unanimous vote to seek shareholder approval of certain proposals by written consent that, to adopt and effectuate, will require the majority consent of our stockholders. As of the date of this filing on Form 10-K, we have submitted these proposals to our stockholders pursuant to our definitive proxy statement on Schedule 14A, filed on March 2, 2017 with the Securities and Exchange Commission ("SEC"). Under the proposals we are soliciting our stockholders written consent to approve the filing of an amended and restated certificate of incorporation in Delaware (“Restated Charter”), to increase the number of authorizes shares of our Common Stock, $ 0.0001 500,000,000 750,000,000 Included within our definitive proxy statement on Schedule 14A, filed as of March 2, 2017 with the SEC, we submitted a proposal to our stockholders for written consent to approve the filing of an amended and restated certificate of incorporation in Delaware (the “Restated Charter”) or in a subsequent amendment to the Restated Charter, provisions to effect a reverse split of our issued and outstanding Common Stock, within a range of not less than one-for-fifteen (1:15) and not more than one-for-fifty (1:50), with such ratio to be determined by the Board of Directors, in its sole discretion (the “Reverse Split”), and with such Reverse Split to be effective at such time and date within one year after the date such action is approved by the stockholders, if at all, as determined by the Board of Directors in its sole discretion (the “Reverse Split Proposal”). The Reverse Split proposal, including the final reduced number of shares of Common Stock into which our currently outstanding shares will be converted (within the stockholder-approved range referred to above), if approved by the consent of a majority of our stockholders, will be determined by our Board of Directors in order to list our Common Stock on the Nasdaq Capital Market which, in any event, shall become effective only (a) upon the approved filing of the Restated Charter to consummate the Reverse Split with the Secretary of State of the State of Delaware, including the final reduced number of shares of Common Stock into which our currently outstanding shares will be converted; and (b) upon announcement of the Reverse Split by FINRA. In the event that we receive written consent from a majority of our stockholders entitled to vote thereunder approving the Reverse Split and, subsequently, our Board of Directors elects to consummate the Reverse Split on or prior to March 31, 2017, the Board of Directors will not If implemented, the Reverse Stock Split will only effect our outstanding Common Stock and shares of Common Stock issuable upon conversion of convertible securities and exercise of warrants and options. It will not effect the number of shares of Common Stock we are authorized to issue under our Restated Charter. The purpose of the Reverse Split is to enable us to qualify our Common Stock for listing on a national stock exchange such as The Nasdaq Capital Market or the NYSE AMEX. Our Common Stock is currently traded on the OTC Markets OTCQB marketplace. Such trading market is considered to be less efficient than that provided by a stock exchange such as The Nasdaq Stock Market or NYSE AMEX. In order for us to list our Common Stock on The Nasdaq Stock Market or NYSE MKT, we must fulfill certain listing requirements, including minimum bid price requirements for our Common Stock. On April 4, 2017, the Company’s board of directors approved the Company’s decision to exercise such discretionary right by extending the deadline to receive written consents under the Consent Solicitation from the original date of March 30, 2017 to April 28, 2017. As of April 24, 2017, the Company has received the written consent of more than a majority of the voting power of its Common Stock outstanding as of the Record Date in favor of the Proposals and terminated the Consent Solicitation period. See Note 18 Evaluations of Subsequent Events for additional information related to the proxy. Conversion of Obligations to Stockholder In March 2017, related parties converted $ 2,516,719 92,319 34,787,162 0.075 34,787,162 0.09 34,787,162 0.1125 Sale of Common Stock In January through March 2017 (the “Closing”), the Company received an aggregate of $ 688,000 68.80 Pursuant to its private placement memorandum, dated as of October 31, 2016 (the “Memorandum”), the Company is offering, through a placement agent, a maximum of 500 Units of securities at a price of $10,000 per Unit for up to $5,000,000 in gross proceeds (the “Offering”). Each Unit consists of up to (a) 133,333.33 shares of Common Stock, par value $0.0001 (the “Common Stock”), (b) 18 month warrants to purchase 133,333.33 shares of Common Stock at an exercise price of $0.09 per share (the “Class A Warrants”), and (c) five year warrants to purchase 133,333.33 shares of Common Stock at an exercise price of $0.1125 per share (the “Class B Warrants” and together with the Class A Warrants, the “Investor Warrants”). If all 500 Units are sold, the Company will issue an aggregate of 66,666,667 shares of its Common Stock and Investor Warrants to purchase up to 133,333,334 shares of Common Stock. The Offering terminated on March 31, 2017. In connection with the Closing, the Company issued an aggregate of 9,173,331 0.075 9,173,331 0.09 9,173,331 0.1125 The Company intends to consummate a 1-for-50 reverse stock split of its outstanding Common Stock following the termination date of the Offering, which reverse split has previously been authorized by the Company’s stockholders. Consummation of the Reverse Stock Split will require (a) the filing of an amendment to the Company’s Certificate of Incorporation with the Delaware Secretary of State, and (b) obtaining the approval of FINRA. In connection with the Closing, the Company paid to the placement agent an aggregate of $ 88,040 2,222,000 0.075 In connection with the Closing, the Company also entered into a Registration Rights Agreement (the “Registration Rights Agreement”) with each of the Purchasers, which requires the Company to file a registration statement (the “Registration Statement”) with the Securities and Exchange Commission (the “Commission”) registering for resale (i) all Common Stock issued to the Purchasers as part of the Units, (ii) all shares of Common Stock issuable upon exercise of the Investor Warrants and the warrants issued to the placement agent, and (iii) all shares of Common Stock issued to legal counsel for services rendered in connection with the Closing. If the Registration Statement is not declared effective by the SEC within the specified deadlines set forth in the Registration Rights Agreement, the Company will be required to pay to each Purchaser an amount in cash, as partial liquidated damages, equal to 1.0 6 18 The sale of Common Stock from November through March 2017 (see above) was completed at a unit price of $ 0.075 85,724,996 25,244,336 49,459,532 Consultant Agreements On January 31, 2017, the Board of Directors approved payment of $ 50,000 666,667 0.075 666,667 0.09 666,667 0.1125 On January 31, 2017, the Board of Directors approved payment of 2,000,000 In February 2017, the Company has issued an aggregate of 750,000 500,000 250,000 250,000 250,000 250,000 In March 2017, the Company entered into a consulting agreement with a firm for professional financial advisory and introductory services for a period is from March 8, 2017 through December 31, 2017. Besides a one-time $ 10,000 1,200,000 Anti-Dilution Triggering Event The sale of Common Stock in the 2016/17 Offering was completed at a unit price of $ 0.075 85,724,996 25,244,336 49,459,532 Shares Price Estimated issued and per Gross fair value at Par Additional outstanding share proceeds issuance value paid-in capital Balance as of December 31, 2016 162,471,373 Various $ 59,801,216 $ 2,951,293 $ 16,247 $ 62,440,674 Issuance (a) 9,173,330 $ 0.075 688,000 – 917 563,508 Issuance (b) 3,416,667 $ various – 230,000 342 229,658 Issuance (c) 34,787,162 $ 0.075 – 2,609,037 3,479 2,605,558 Balance as of March 31, 2017 209,848,532 (d) $ 60,489,216 $ 5,790,330 $ 20,985 $ 65,839,398 (a) Shares issued in conjunction with the 2016/17 Offering and contains no anti-dilution provisions (b) Shares issued in conjunction with certain Consultant Agreements (c) Shares issued for conversion of debt and interests. Shares do not contain anti-dilution provisions (d) Includes 21,214,642

Stock Options and Stock-Based C

Stock Options and Stock-Based Compensation	3 Months Ended
	Mar. 31, 2017
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Stock Options and Stock Based Compensation [Text Block]	14. Stock Options and Stock-Based Compensation In 2002, the Board adopted the 2002 Equity Incentive Plan (the “2002 Plan”) that governed equity awards to employees, members of the Board of Directors, and consultants of the Company. Under the 2002 Plan, 450,000 4,150,000 12,500,000 The types of awards permitted under the Plans include qualified incentive stock options (“ISO”), non-qualified stock options (“NQO”), and restricted stock. Each stock option shall be exercisable at such times and subject to such terms and conditions as the Board of Directors may specify. Stock options generally vest over four (4) years and expire no later than ten (10) years from the date of grant. Weighted average Weighted ave. remaining Stock options exercise price contractual life (years) Outstanding as of December 31, 2016 10,780,086 $ 0.57 7.30 Granted 560,000 $ 0.15 Exercised – $ – Cancelled or expired (430,000) $ 0.48 Outstanding as of March 31, 2017 10,910,086 $ 0.55 7.20 Exercisable as of December 31, 2016 5,680,899 $ 0.84 5.70 Exercisable as of March 31, 2017 5,871,656 $ 0.81 5.72 Stock options outstanding Stock options exercisable Weighted Weighted Weighted average average average remaining contractual exercise exercise Exercise price Outstanding life (in years) price Exercisable price $ 0.15 3,560,000 375,000 $ 0.25 1,573,336 839,592 $ 0.48 150,000 56,250 $ 0.50 79,000 79,000 $ 0.53 325,000 142,188 $ 0.55 3,312,000 2,468,876 $ 1.25 50,000 50,000 $ 1.50 1,646,000 1,646,000 $ 2.00 214,750 214,750 $0.15 – $2.00 10,910,086 7.20 $ 0.55 5,871,656 $ 0.81 As of March 31, 2017, the total aggregate intrinsic value for stock options currently exercisable and stock options outstanding was estimated to be $ 0 0.08 Weighted average grant-date fair Stock options value (per option) Non-vested as of December 31, 2016 5,340,687 $ 0.12 Granted 560,000 $ 0.15 Forfeited (279,375) $ 0.21 Vested (582,882) $ 0.07 Non-vested as of March 31, 2017 5,038,430 $ 0.24 The fair value of non-vested stock options to be recognized in future periods is $ 588,548 2.57 41,208 63,800 Three Months Ended March 31, 2017 2016 Selling, general, and administrative expense $ 37,822 $ 58,018 Research and development expense 3,386 5,782 Total stock-based compensation $ 41,208 $ 63,800 The weighted average grant-date fair value of stock options granted during the three months ended March 31, 2017 was $ 0.097 0 Three Months Ended March 31, 2017 2016 Weighted average risk-free interest rate 2.12 % N/A % Volatility factor 66.32 % N/A % Weighted average expected life (in years) 7 N/A Dividend rate 0 % N/A % The Company utilizes a peer group to estimate its expected volatility assumptions used in the Black-Scholes option-pricing model. The Company completed an analysis and identified four similar public companies considering their industry, stage of life cycle, size, and financial leverage. Given the Company’s limited history with stock options, the Company’s expected term is based on an average of the contractual term and the vesting period of the options (the SEC Staff Accounting Bulletin No. 110, “Simplified” method).

Warrants

Warrants	3 Months Ended
	Mar. 31, 2017
Stock Warrants [Abstract]
Stock Warrants [Text Block]	15. Warrants See Note 12 Debt and Note 13 Common Stock for information related to the issuance of warrants to related parties, WVJITB, Consultants, Investors and a placement agent for the purchase of 69,574,324 750,000 2,222,000 As of March 31, 2017, warrants to purchase 214,206,968 150,158 Weighted Weighted average average remaining exercise contractual life Warrants price (in years) Outstanding as of December 31, 2016 122,475,881 $ 0.43 2.13 Granted 92,612,986 $ 0.10 3.83 Exercised – $ Cancelled or expired (881,899) $ 1.90 Outstanding as of March 31, 2017 214,206,968 (a) $ 0.25 2.81 (a) includes 57,488,533 Warrants Outstanding Weighted Average Remaining Weighted Average Exercise Price Outstanding Contractual Life (in years) Exercise Price $ 0.075 7,463,720 $ 0.090 63,592,889 $ 0.100 1,810,000 $ 0.110 1,250,000 $ 0.1125 63,592,889 $ 0.190 4,654,145 $ 0.240 7,500,000 $ 0.270 14,831,098 $ 0.280 2,845,000 $ 0.325 8,029,001 $ 0.375 741,000 $ 0.400 1,040,000 $ 0.450 1,730,000 $ 0.500 13,315,667 $ 0.740 7,309,395 $ 0.750 491,250 $ 0.800 1,415,000 $ 1.100 11,773,275 $ 1.120 263,750 $ 2.200 70,000 $ 2.250 488,889 $0.075 - $2.250 214,206,968 2.81 $ 0.25

Commitments and Contingencies

Commitments and Contingencies	3 Months Ended
	Mar. 31, 2017
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies Disclosure [Text Block]	16. Commitments and Contingencies Legal Proceedings The Company currently is not a party to any material legal proceeding and has no knowledge of any material legal proceeding contemplated by any governmental authority or third party. The Company may be subject to a number of claims and legal proceedings which, in the opinion of our management, are incidental to normal business operations. In managements’ opinion, although final settlement of these claims and suits may impact the financial statements in a particular period, they will not, in the aggregate, have a material adverse effect on the Company’s financial position, cash flows or results of operations. In 2016, the Company had received three court summons for past due accounts payables. The claims total $ 213,032 161,889 25,000 111,889.16 37,000 Warranty Reserve The Company provides for a one-year warranty with the sale of its LAESI® instruments. As the Company does not currently have sufficient historical data on warranty claims, the Company’s estimates of anticipated rates of warranty claims and costs are primarily based on comparable industry metrics. The Company engages in extensive product quality programs and processes, including actively monitoring and evaluating the quality of its products. As of March 31, 2017, and December 31, 2016, the Company had accrued warranty expense of $ 35,000 45,000 University License Agreements The Company has agreements with West Virginia University (“WVU”) and George Washington University (GWU) related to in-licensed technologies as follows: WVU The Company has entered into a License and Exclusive Option to License Agreement with the West Virginia University Research Corporation (“WVURC”), a nonprofit West Virginia corporation acting for and on behalf of WVU. Under the terms of this agreement, the WVURC has granted the Company an exclusive option to license technology from the laboratories of certain WVU principal investigators in the field of protein discovery, for therapeutic, diagnostic and all other commercial fields worldwide. Under the terms of this Agreement, the Company pays expenses for the preparation, filing and prosecution of related patent applications, and the Company will pay royalties on the net revenue resulting from the sale of products and services that utilize the WVU subject technology. GWU I n March 2009, the Company entered into an Exclusive License Agreement with GWU for technology developed in the laboratory of Dr. Akos Vertes Ph.D., Professor of Chemistry, Professor of Biochemistry & Molecular Biology, Founder and Co-Director of the W.M. Keck Institute for Proteomics Technology and Applications, the Department of Chemistry, who is a science advisor to the Company. The technology field is laser ablation electrospray ionization, or “LAESI”, a new method of bioanalytical analysis that enables high throughput biomolecule characterization. Under the terms of this agreement, the Company has the exclusive, worldwide rights to commercialize the technology. The Company has obtained a registered trademark for “LAESI®”. The Company is obligated to pay expenses for the preparation, filing and prosecution of related patent applications, and the Company pays royalties on the net revenues resulting from the sale of products and services that utilize the GWU subject technology. During the three months ended March 31, 2017, the Company recorded royalty expenses of $ 699 1,257 In January 2017, the Company had received a Payment on Demand letters from George Washington University regarding exclusive license agreement for the “LAESI License” along with the patent license agreement for the “Protein Microscope License.” As these letters relate to such agreements and past due payments they allow the Company to make payment or release their rights of the each of such license agreements by specified amount of days for each agreement or provide requested plans. George Washington University requests that all LAESI License past due royalties and interest of $ 110,374 As of March 31, 2017, the Company’s accounts payable balance included $ 47,700 0 In January 2014, the Company became a subcontractor to GWU in a multi-year project with the Defense Advanced Research Projects Agency (“DARPA”) to develop new tools and methods to elucidate the mechanism of action of a threat agent, drug, biologic or chemical on living cells within thirty (30) days of exposure. This product is called REDIchip™ (an acronym for Resonance-Enhanced Desorption Ionization). Yale In April 2016, we entered into an exclusive license agreement for technology with Yale University related to the differential diagnosis of melanoma, specifically designated as a "Method of Differentiating Benign Melanocytic Nevi from Malignant Melanoma." The technology was co-invented by Dr. Rossitza Lazova, of the Department of Dermatology at Yale School of Medicine, and Dr. Erin Seeley our Principal Investigator. Under the terms of the license agreement, we have been granted the exclusive worldwide rights to commercialize the technology. We are obligated to pay expenses for the preparation, filing and prosecution of future related patent applications governed by the license agreement and related license fees. We are obligated to pay a non-refundable royalty of $ 5,000 2,500 5,000 5,000 7,500 10,000 2.5 10,000 15,000 20,000 30,000 40,000 50,000

Supplemental Cash Flow Informat

Supplemental Cash Flow Information	3 Months Ended
	Mar. 31, 2017
Supplemental Cash Flow Elements [Abstract]
Cash Flow, Supplemental Disclosures [Text Block]	17. Supplemental Cash Flow Information Cash paid for interest and income taxes During the three months ended March 31, 2017, cash paid for interest totaled $ 104,566 47,459 Non-cash investing and financing activities Three Months Ended March 31, 2017 2016 Equipment acquired under capital leases $ – $ 18,344 Issuance of common stock upon conversion of accrued interest $ – $ 41,393 Issuance of common stock upon conversion of related party debt and interest $ 2,614,037 $ – Issuance costs for short-term debt $ – $ 5,000 Fair value of warrant committed to placement agent $ – $ 2,456

Evaluation of Subsequent Events

Evaluation of Subsequent Events	3 Months Ended
	Mar. 31, 2017
Subsequent Events [Abstract]
Subsequent Events [Text Block]	18. Evaluation of Subsequent Events Convertible Note Subsequent to March 31, 2017, we issued our legal counsel, CKR Law LLP a $ 308,439 September 30, 2017 85 Senior Secured Convertible Note On April 7, 2017, we received a loan of $ 1,750,000 300,000 1,250,000 36 Of the loan proceeds, $ 1,250,000 30 500,000 5,000,000 Commencing 30 days after installation of the Instrument we will pay monthly installments of principal and accrued interest in the amount equal to the greater of (a) $ 62,030.86 36 interest at the rate of 15% per annum), or (b) 20% of the cash proceeds we receive from customers who request services from the Company using the new mass spectrometer equipment The Note is convertible into shares of our Common Stock, at the option of the holder at a conversion price equal to the lower 0.075 85 The loan is secured by a first lien and security interest on all of our assets and properties, including the purchased equipment and all purchase orders we receive in connection therewith. In a related development on April 21, 2017, we entered into an agreement with Summit under which Summit: • Consented to the exchange agreement with GRQ and waived any defaults on our part under the Summit loan agreement; and • agreed to waive its security interest in the GRQ Collateral until such time as we pay the $ 301,577.79 The Company and our subsidiary reaffirmed Summit’s senior priority lien and security interest on all of our assets and properties, other than the specific GRQ Collateral. Proxy As of April 24, 2017, the Company has received the written consent of more than a majority of the voting power of its Common Stock outstanding as of the Record Date in favor of the Proposals and terminated the Consent Solicitation period. The Company filed the Restated Charter with the Secretary of State of the State of Delaware on April 25, 2017. September 2016 10% OID Secured Promissory Note On April 20, 2017, we entered into an exchange agreement with GRQ Consulting Inc. 401k (‘GRQ”) under Section 3(a)(9) of the Securities Act of 1933, as amended. Under the terms of the exchange agreement, GRQ exchanged the Original GRQ Note for a new Company note that requires the Borrowers to pay in full the overdue $ 301,577.79 375,000 0.075 5,000,000 375,000 The guaranty of our Protea subsidiary and GRQ’s security interest in the GRQ collateral remain in full force and effect pending our payment of the $ 301,577.79 In a related development on April 21, 2017, we entered into an agreement with Summit under which Summit: • Consented to the exchange agreement with GRQ and waived any defaults on our part under the Summit loan agreement; and • Agreed to waive its security interest in the GRQ Collateral until such time as we pay the $301,577.79 obligation to GRQ. The Company and our subsidiary reaffirmed Summit’s senior priority lien and security interest on all of our assets and properties, other than the specific GRQ Collateral. Obligations to Stockholders Subsequent to March 31, 2017, the Company received advances totaling $ 415,000 Executed Consulting Agreements Subsequent to March 31, 2017 the Company has entered into one (1) consulting agreement. This agreement was entered into for business advisory services and has a term period from April 24, 2017 through December 31, 2017. The Company will compensate the Consultant by issuing 250,000 Sale of Investment Subsequent to March 31, 2017 the Company sold 25,000 85,355 1.36 100,757

Gross Revenue (Tables)

Gross Revenue (Tables)	3 Months Ended
	Mar. 31, 2017
Segment Reporting [Abstract]
Revenue from External Customers by Products and Services [Table Text Block]	The Company recognizes revenue from three major components: molecular information services, LAESI® instrument platform and research products. Three Months Ended March 31, 2017 2016 Molecular information services $ 257,753 $ 217,052 LAESI® instrument platform 6,883 179,795 Research products 90,200 78,791 Gross revenue $ 354,836 $ 475,338

Fair Value of Financial Asset27

Fair Value of Financial Assets and Liabilities - Derivative Financial Instruments (Tables)	3 Months Ended
	Mar. 31, 2017
Fair Value Disclosures [Abstract]
Fair Value Inputs, Instruments Classified in Shareholders' Equity, Quantitative Information [Table Text Block]	As of March 31, 2017, a range of key quantitative assumptions related to the Common Stock and warrants that include “down round protection” are as follows: Expected life (years) Risk-free rate Volatility Probability of a capital raise Derivative liabilities 0.50 – 5.00 0.91% and 1.27% 81.05 % 100 %
Fair Value, by Balance Sheet Grouping [Table Text Block]	The derivative liabilities measured at fair value on a recurring basis are summarized below: Fair value measurements as of March 31, 2017 Carrying value Level 1 Level 2 Level 3 Derivative liabilities – Common Stock $ 2,581,090 $ – $ – $ 2,581,090 Derivative liabilities – Warrants 3,710,217 – – 3,710,217 Derivative liabilities – Convertible debentures 632,817 – – 632,817 Total $ 6,924,124 $ – $ – $ 6,924,124 Fair value measurements as of December 31, 2016 Carrying value Level 1 Level 2 Level 3 Derivative liabilities – Common Stock $ 2,016,370 $ – $ – $ 2,016,370 Derivative liabilities – Warrants 854,553 – – 854,553 Derivative liabilities – Convertible debentures 226,998 – – 226,998 Total $ 3,097,921 $ – $ – $ 3,097,921
Fair Value Measurements, Recurring and Nonrecurring [Table Text Block]	The table below provides a summary of the changes in fair value of the derivative liabilities measured at fair value on a recurring basis: Three Months Ended March 31, 2017 Total fair value Derivative liabilities measurements Common Convertible using Level 3 stock Warrants debt inputs Balance as of December 31, 2016 $ 2,016,370 $ 854,553 $ 226,998 $ 3,097,921 Unrealized loss on derivative liabilities outstanding as of December 31, 2016 564,720 1,725,474 – 2,290,194 Fair value of variable conversion rate for convertible debentures issued in 2017 – – 405,819 405,819 Fair value of derivative liabilities associated with other financial instruments issued in 2017 – 1,130,190 – 1,130,190 Balance as of March 31, 2017 $ 2,581,090 $ 3,710,217 $ 632,817 $ 6,924,124

Inventory (Tables)

Inventory (Tables)	3 Months Ended
	Mar. 31, 2017
Inventory Disclosure [Abstract]
Schedule of Inventory, Current [Table Text Block]	Inventory represents finished goods and work in progress. Finished goods and work in progress consist primarily of specifically identifiable items that are valued at the lower of cost or fair market value using the first-in, first-out (FIFO) method. Inventory consists of the following at: March 31, 2017 December 31, 2016 Finished goods $ 10,307 $ 8,725 Work-in progress 30,311 83,519 Total inventory $ 40,618 $ 92,244

Property and Equipment (Tables)

Property and Equipment (Tables)	3 Months Ended
	Mar. 31, 2017
Property, Plant and Equipment [Abstract]
Property Plant And Equipment Useful Life [Table Text Block]	Property and equipment and leasehold improvements are capitalized at cost and depreciated using the straight-line method (the Company used the double-declining balance method for property and equipment placed in service prior to January 2011) over estimated lives as follows: Equipment 5 – 10 years Vehicles 5 years Leasehold improvements Life of lease Software 3 years
Property, Plant and Equipment [Table Text Block]	Property and equipment consists of the following: March 31, 2017 December 31, 2016 Lab equipment $ 5,701,039 $ 5,698,009 Computer equipment 552,423 552,423 Office equipment 191,248 191,248 Leasehold improvements 212,730 212,730 6,657,440 6,654,410 Accumulated depreciation (4,318,639) (4,188,285) Property and equipment, net $ 2,338,801 $ 2,466,125

Other Current Liabilities (Tabl

Other Current Liabilities (Tables)	3 Months Ended
	Mar. 31, 2017
Payables and Accruals [Abstract]
Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]	Other current liabilities consist of the following at: March 31, 2017 December 31, 2016 Accrued expenses $ 33,358 $ 68,411 Accrued interest 304,266 264,507 Accrued warranty expense 35,000 45,000 Accrued payroll and benefits 189,322 119,619 Accrued sales tax – 103 Unearned revenue 55,572 58,407 Other payables and accrued expenses $ 617,518 $ 556,047

Debt (Tables)

Debt (Tables)	3 Months Ended
	Mar. 31, 2017
Debt Disclosure [Abstract]
Schedule of Long-term Debt Instruments [Table Text Block]	Total outstanding debt, including capital lease obligations, are as follows (table excludes the outstanding balance of the bank line of credit because it was presented as a current liability, as discussed in Note 9 Bank Line of Credit; table also excludes obligations to stockholders, which are detailed in Note 10 Obligations to Stockholders and presented as a separate line item on the Company’s Consolidated Balance Sheets): March 31, 2017 December 31, 2016 1) Note Payable to the WVDO $ 92,873 $ 92,873 2) Note Payable to the WVEDA (a) 143,312 143,312 3) Note Payable to the WVIJDC (b) 139,229 139,229 4) Note Payable to the WVEDA (a) 572,148 572,148 5) Note Payable to the WVIJDC (b) 581,987 581,987 6) Note Payable to the WVJITB 290,000 290,000 7) Note Payable to the WVJITB 300,000 300,000 8) Note Payable to the WVEDA (a) 168,362 168,362 9) Convertible Debenture 2 nd rd 2,114,438 2,114,438 10) September 2016 10% OID Secured Promissory Note 280,000 480,000 11) September 2016 20% OID Note 156,250 156,250 12) Short-term Convertible Note in March 2016 – - 13) Capital leases 818,979 928,530 Total 5,657,578 5,967,129 Less: current portion (3,798,276) (4,012,149) Less: unamortized original issue discount – (22,001) Less: unamortized debt issuance costs (25,051) (163,624) Long-term portion $ 1,834,251 $ 1,769,355 (a) West Virginia Economic Development Authority (b) West Virginia Infrastructure and Jobs Development Council
Schedule of Maturities of Long-term Debt [Table Text Block]	Future required minimum principal repayments over the next five years are as follows (same exclusions as noted for the table above): Future required minimum Year Ended December 31: principal payments 2017 $ 3,733,206 2018 534,352 2019 500,357 2020 495,353 2021 and thereafter 394,310 Total $ 5,657,578

Common Stock (Tables)

Common Stock (Tables)	3 Months Ended
	Mar. 31, 2017
Common Stock [Member]
Schedule of Stock by Class [Table Text Block]	Common Stock issued and outstanding is as follows: Shares Price Estimated issued and per Gross fair value at Par Additional outstanding share proceeds issuance value paid-in capital Balance as of December 31, 2016 162,471,373 Various $ 59,801,216 $ 2,951,293 $ 16,247 $ 62,440,674 Issuance (a) 9,173,330 $ 0.075 688,000 – 917 563,508 Issuance (b) 3,416,667 $ various – 230,000 342 229,658 Issuance (c) 34,787,162 $ 0.075 – 2,609,037 3,479 2,605,558 Balance as of March 31, 2017 209,848,532 (d) $ 60,489,216 $ 5,790,330 $ 20,985 $ 65,839,398 (a) Shares issued in conjunction with the 2016/17 Offering and contains no anti-dilution provisions (b) Shares issued in conjunction with certain Consultant Agreements (c) Shares issued for conversion of debt and interests. Shares do not contain anti-dilution provisions (d) Includes 21,214,642

Stock Options and Stock-Based33

Stock Options and Stock-Based Compensation (Tables)	3 Months Ended
	Mar. 31, 2017
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]	A summary of stock option activity is as follows: Weighted average Weighted ave. remaining Stock options exercise price contractual life (years) Outstanding as of December 31, 2016 10,780,086 $ 0.57 7.30 Granted 560,000 $ 0.15 Exercised – $ – Cancelled or expired (430,000) $ 0.48 Outstanding as of March 31, 2017 10,910,086 $ 0.55 7.20 Exercisable as of December 31, 2016 5,680,899 $ 0.84 5.70 Exercisable as of March 31, 2017 5,871,656 $ 0.81 5.72
Schedule of Share-based Compensation, Shares Authorized under Stock Option Plans, by Exercise Price Range [Table Text Block]	The following table summarizes information about stock options at March 31, 2017: Stock options outstanding Stock options exercisable Weighted Weighted Weighted average average average remaining contractual exercise exercise Exercise price Outstanding life (in years) price Exercisable price $ 0.15 3,560,000 375,000 $ 0.25 1,573,336 839,592 $ 0.48 150,000 56,250 $ 0.50 79,000 79,000 $ 0.53 325,000 142,188 $ 0.55 3,312,000 2,468,876 $ 1.25 50,000 50,000 $ 1.50 1,646,000 1,646,000 $ 2.00 214,750 214,750 $0.15 – $2.00 10,910,086 7.20 $ 0.55 5,871,656 $ 0.81
Schedule of Nonvested Share Activity [Table Text Block]	The following table summarizes the activity of the Company’s stock options that have not yet vested: Weighted average grant-date fair Stock options value (per option) Non-vested as of December 31, 2016 5,340,687 $ 0.12 Granted 560,000 $ 0.15 Forfeited (279,375) $ 0.21 Vested (582,882) $ 0.07 Non-vested as of March 31, 2017 5,038,430 $ 0.24
Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block]	Stock-based compensation expense is as follows: Three Months Ended March 31, 2017 2016 Selling, general, and administrative expense $ 37,822 $ 58,018 Research and development expense 3,386 5,782 Total stock-based compensation $ 41,208 $ 63,800
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]	The fair value of the stock option grants was estimated using the Black-Scholes option-pricing model with the following weighted average assumptions: Three Months Ended March 31, 2017 2016 Weighted average risk-free interest rate 2.12 % N/A % Volatility factor 66.32 % N/A % Weighted average expected life (in years) 7 N/A Dividend rate 0 % N/A %

Warrants (Tables)

Warrants (Tables)	3 Months Ended
	Mar. 31, 2017
Stock Warrants [Abstract]
Schedule Of Warrant Activity [Table Text Block]	Weighted Weighted average average remaining exercise contractual life Warrants price (in years) Outstanding as of December 31, 2016 122,475,881 $ 0.43 2.13 Granted 92,612,986 $ 0.10 3.83 Exercised – $ Cancelled or expired (881,899) $ 1.90 Outstanding as of March 31, 2017 214,206,968 (a) $ 0.25 2.81 (a) includes 57,488,533
Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]	Warrants Outstanding Weighted Average Remaining Weighted Average Exercise Price Outstanding Contractual Life (in years) Exercise Price $ 0.075 7,463,720 $ 0.090 63,592,889 $ 0.100 1,810,000 $ 0.110 1,250,000 $ 0.1125 63,592,889 $ 0.190 4,654,145 $ 0.240 7,500,000 $ 0.270 14,831,098 $ 0.280 2,845,000 $ 0.325 8,029,001 $ 0.375 741,000 $ 0.400 1,040,000 $ 0.450 1,730,000 $ 0.500 13,315,667 $ 0.740 7,309,395 $ 0.750 491,250 $ 0.800 1,415,000 $ 1.100 11,773,275 $ 1.120 263,750 $ 2.200 70,000 $ 2.250 488,889 $0.075 - $2.250 214,206,968 2.81 $ 0.25

Supplemental Cash Flow Inform35

Supplemental Cash Flow Information (Tables)	3 Months Ended
	Mar. 31, 2017
Supplemental Cash Flow Elements [Abstract]
Schedule of Cash Flow, Supplemental Disclosures [Table Text Block]	The Company did not pay any income taxes during 2016 or the three months ended March 31, 2017. Non-cash investing and financing activities Three Months Ended March 31, 2017 2016 Equipment acquired under capital leases $ – $ 18,344 Issuance of common stock upon conversion of accrued interest $ – $ 41,393 Issuance of common stock upon conversion of related party debt and interest $ 2,614,037 $ – Issuance costs for short-term debt $ – $ 5,000 Fair value of warrant committed to placement agent $ – $ 2,456

Description of Business and B36

Description of Business and Basis of Presentation (Details Textual) - USD ($)	1 Months Ended		3 Months Ended
	Apr. 30, 2017	Oct. 31, 2016	Mar. 31, 2017	Mar. 31, 2016	Sep. 30, 2017	Apr. 07, 2017	Dec. 31, 2016
Nature of Business [Line Items]
Increase (Decrease) in Accounts Payable			$ (84,146)	$ (59,862)
Proceeds from Issuance of Debt			688,000
Long-term Line of Credit			$ 3,000,000
Stock Issued During Period, Shares, New Issues		9,173,331	9,173,332
Class of Warrant or Right, Number of Securities Called by Warrants or Rights			18,346,662
Common Stock, Capital Shares Reserved for Future Issuance			12,500,000
Expected Number Of Shares To Be Issued			85,724,996				85,724,996
Accounts Payable, Trade, Current			$ 1,712,272				$ 1,796,416
Substantial Doubt about Going Concern, Conditions or Events			We will remain an “emerging growth company” for up to five years following our initial public offering, that is, until February 2019, although we will lose that status sooner if our revenues exceed $1 billion, if we issue more than $1 billion in non-convertible debt in a three-year period, or if the market value of our common stock that is held by non-affiliates exceeds $700 million as of any June 30.
Insider Debt Conversion Agreement [Member]
Nature of Business [Line Items]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights			69,574,324
Decreased in Debt Obligation to Shareholders			$ 2,516,719
Stock and Warrants Issued During Period, Shares, Common Stock and Warrants			34,787,162
Subsequent Event [Member]
Nature of Business [Line Items]
Debt Instrument, Face Amount						$ 1,750,000
License Agreement Terms [Member]
Nature of Business [Line Items]
Accrued Liabilities			$ 1,290,244
AzurRx BioPharma Inc [Member]
Nature of Business [Line Items]
Equity Method Investment, Ownership Percentage			1.70%
Sale of Stock, Number of Shares Issued in Transaction			125,757
Common Stock, Capital Shares Reserved for Future Issuance			100,000
Sale of Stock, Price Per Share			$ 1
AzurRx BioPharma Inc [Member] | Subsequent Event [Member]
Nature of Business [Line Items]
Equity Method Investment, Ownership Percentage	1.36%
Sale of Stock, Number of Shares Issued in Transaction	25,000
Exchange Notes [Member]
Nature of Business [Line Items]
Debt Instrument, Interest Rate, Stated Percentage					10.00%
Debt Instrument, Maturity Date			Sep. 30, 2017
Debt Instrument, Face Amount			$ 2,384,222
Past Due 90 Days [Member]
Nature of Business [Line Items]
Increase (Decrease) in Accounts Payable			1,290,244
Overdue Terms [Member]
Nature of Business [Line Items]
Increase (Decrease) in Accounts Payable			$ 1,558,698

Gross Revenue (Details)

Gross Revenue (Details) - USD ($)	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Segment Reporting Information [Line Items]
Gross Revenue	$ 354,836	$ 475,338
Molecular Information Services [Member]
Segment Reporting Information [Line Items]
Gross Revenue	257,753	217,052
LAESI Instrument Platform [Member]
Segment Reporting Information [Line Items]
Gross Revenue	6,883	179,795
Research Products [Member]
Segment Reporting Information [Line Items]
Gross Revenue	$ 90,200	$ 78,791

Fair Value of Financial Asset38

Fair Value of Financial Assets and Liabilities - Derivative Financial Instruments (Details)	3 Months Ended
	Mar. 31, 2017
Minimum [Member]
Fair Value Inputs, Liabilities, Quantitative Information [Line Items]
Fair Value Assumptions, Expected Term	6 months
Fair Value Assumptions, Risk Free Interest Rate	0.91%
Maximum [Member]
Fair Value Inputs, Liabilities, Quantitative Information [Line Items]
Fair Value Assumptions, Expected Term	5 years
Fair Value Assumptions, Risk Free Interest Rate	1.27%
Derivative Financial Instruments, Liabilities [Member]
Fair Value Inputs, Liabilities, Quantitative Information [Line Items]
Fair Value Assumptions, Expected Volatility Rate	81.05%
Probability of Future Capital Raises	100.00%

Fair Value of Financial Asset39

Fair Value of Financial Assets and Liabilities - Derivative Financial Instruments (Details 1) - USD ($)	Mar. 31, 2017	Dec. 31, 2016
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Derivative Liability	$ 6,924,124	$ 3,097,921
Derivative liabilities - Convertible Debt [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Derivative Liability	632,817	226,998
Fair Value, Inputs, Level 1 [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Derivative Liability	0	0
Fair Value, Inputs, Level 1 [Member] | Derivative liabilities - Convertible Debt [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Derivative Liability	0	0
Fair Value, Inputs, Level 2 [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Derivative Liability	0	0
Fair Value, Inputs, Level 2 [Member] | Derivative liabilities - Convertible Debt [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Derivative Liability	0	0
Fair Value, Inputs, Level 3 [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Derivative Liability	6,924,124	3,097,921
Fair Value, Inputs, Level 3 [Member] | Derivative liabilities - Convertible Debt [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Derivative Liability	632,817	226,998
Derivative liabilities - common stock [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Derivative Liability	2,581,090	2,016,370
Derivative liabilities - common stock [Member] | Fair Value, Inputs, Level 1 [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Derivative Liability	0	0
Derivative liabilities - common stock [Member] | Fair Value, Inputs, Level 2 [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Derivative Liability	0	0
Derivative liabilities - common stock [Member] | Fair Value, Inputs, Level 3 [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Derivative Liability	2,581,090	2,016,370
Derivative liabilities - warrant [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Derivative Liability	3,710,217	854,553
Derivative liabilities - warrant [Member] | Fair Value, Inputs, Level 1 [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Derivative Liability	0	0
Derivative liabilities - warrant [Member] | Fair Value, Inputs, Level 2 [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Derivative Liability	0	0
Derivative liabilities - warrant [Member] | Fair Value, Inputs, Level 3 [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Derivative Liability	$ 3,710,217	$ 854,553

Fair Value of Financial Asset40

Fair Value of Financial Assets and Liabilities - Derivative Financial Instruments (Details 2)	3 Months Ended
	Mar. 31, 2017USD ($)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Beginning Balance	$ 3,097,921
Ending Balance	6,924,124
Derivative liabilities - Convertible Debt [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Beginning Balance	226,998
Ending Balance	632,817
Derivative liabilities - Convertible Debt [Member] | Fair Value, Measurements, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Beginning Balance	226,998
Unrealized loss on derivative liabilities outstanding as of December 31, 2016	0
Fair value of variable conversion rate for convertible debentures issued in 2017	405,819
Fair value of derivative liabilities associated with other financial instruments issued in 2017	0
Ending Balance	632,817
Derivative liabilities - warrant [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Beginning Balance	854,553
Ending Balance	3,710,217
Derivative liabilities - warrant [Member] | Fair Value, Measurements, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Beginning Balance	854,553
Unrealized loss on derivative liabilities outstanding as of December 31, 2016	1,725,474
Fair value of variable conversion rate for convertible debentures issued in 2017	0
Fair value of derivative liabilities associated with other financial instruments issued in 2017	1,130,190
Ending Balance	3,710,217
Derivative liabilities - common stock [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Beginning Balance	2,016,370
Ending Balance	2,581,090
Derivative liabilities - common stock [Member] | Fair Value, Measurements, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Beginning Balance	2,016,370
Unrealized loss on derivative liabilities outstanding as of December 31, 2016	564,720
Fair value of variable conversion rate for convertible debentures issued in 2017	0
Fair value of derivative liabilities associated with other financial instruments issued in 2017	0
Ending Balance	2,581,090
Fair Value, Inputs, Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Beginning Balance	3,097,921
Ending Balance	6,924,124
Fair Value, Inputs, Level 3 [Member] | Fair Value, Measurements, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Beginning Balance	3,097,921
Unrealized loss on derivative liabilities outstanding as of December 31, 2016	2,290,194
Fair value of variable conversion rate for convertible debentures issued in 2017	405,819
Fair value of derivative liabilities associated with other financial instruments issued in 2017	1,130,190
Ending Balance	6,924,124
Fair Value, Inputs, Level 3 [Member] | Derivative liabilities - Convertible Debt [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Beginning Balance	226,998
Ending Balance	632,817
Fair Value, Inputs, Level 3 [Member] | Derivative liabilities - warrant [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Beginning Balance	854,553
Ending Balance	3,710,217
Fair Value, Inputs, Level 3 [Member] | Derivative liabilities - common stock [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Beginning Balance	2,016,370
Ending Balance	$ 2,581,090

Fair Value of Financial Asset41

Fair Value of Financial Assets and Liabilities - Derivative Financial Instruments (Details Textual)	3 Months Ended
	Mar. 31, 2017$ / shares
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Anti Dilutive Trigger Price	$ 0.075

Net Loss per Share (Details Tex

Net Loss per Share (Details Textual) - shares	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Weighted Average Number of Shares Outstanding, Basic and Diluted	168,961,931	133,299,471
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	278,374,047	80,102,519

Inventory (Details)

Inventory (Details) - USD ($)	Mar. 31, 2017	Dec. 31, 2016
Inventory:
Finished goods	$ 10,307	$ 8,725
Work-in progress	30,311	83,519
Total Inventory	$ 40,618	$ 92,244

Property and Equipment (Details

Property and Equipment (Details)	3 Months Ended
	Mar. 31, 2017
Computer Software, Intangible Asset [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	3 years
Equipment [Member] | Maximum [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	10 years
Equipment [Member] | Minimum [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	5 years
Vehicles [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	5 years
Leasehold Improvements [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Estimated Useful Lives	Life of lease

Property and Equipment (Detai45

Property and Equipment (Details 1) - USD ($)	Mar. 31, 2017	Dec. 31, 2016
Property, Plant and Equipment [Line Items]
Lab equipment	$ 5,701,039	$ 5,698,009
Computer equipment	552,423	552,423
Office equipment	191,248	191,248
Leasehold improvements	212,730	212,730
Property, Plant and Equipment, Gross	6,657,440	6,654,410
Accumulated depreciation	(4,318,639)	(4,188,285)
Property and equipment, net	$ 2,338,801	$ 2,466,125

Property and Equipment (Detai46

Property and Equipment (Details Textual) - USD ($)	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Property, Plant and Equipment [Line Items]
Depreciation, Depletion and Amortization, Total	$ 157,345	$ 158,993

Trade Accounts Receivable and47

Trade Accounts Receivable and Other Noncurrent Assets (Details Textual) - USD ($)	Mar. 31, 2017	Dec. 31, 2016
Other Assets, Noncurrent	$ 19,041	$ 19,041
Allowance for Doubtful Accounts Receivable	1,200	7,000
Deposits [Member]
Other Assets, Noncurrent	$ 19,041	$ 19,041

Bank Line of Credit (Details Te

Bank Line of Credit (Details Textual) - USD ($)	1 Months Ended	3 Months Ended
	Jun. 20, 2016	Mar. 31, 2017	Dec. 31, 2016
Line of Credit Facility [Line Items]
Line of Credit Facility, Maximum Borrowing Capacity (in dollars)		$ 3,000,000	$ 3,000,000
Line of Credit Facility, Interest Rate Description		The interest rate is variable and equal to 0.75% plus prime with a minimum rate of 5.87% per annum.
Line of Credit Facility, Amount Outstanding (in dollars)		$ 3,000,000
Line of Credit [Member]
Line of Credit Facility [Line Items]
Debt Instrument, Maturity Date	Jul. 12, 2018

Obligations to Stockholders (De

Obligations to Stockholders (Details Textual) - USD ($)	Mar. 14, 2017	Mar. 20, 2015	Mar. 31, 2017	Mar. 31, 2016	Mar. 31, 2015	Dec. 31, 2016	Dec. 31, 2014	Oct. 31, 2016	Jun. 03, 2014
Loans Payable to Stockholders [Line Items]
Repayments of Debt			$ 200,000	$ 7,783
Class of Warrant or Right, Number of Securities Called by Warrants or Rights			18,346,662
Warrants and Rights Outstanding									$ 101,177
Debt Instrument, Convertible, Conversion Price			$ 0.075			$ 0.075
Due to Officers or Stockholders, Current			$ 1,191,386			$ 3,087,956
Payments of Debt Issuance Costs			0	$ 60,000
Proceeds from Related Party Debt	$ 255,000
Advance Received From Stockholder			196,319			2,320,400
Interest Receivable			$ 92,319
Conversion of Stock, Shares Converted			34,787,162
Shares Issued, Price Per Share			$ 0.075					$ 0.075
Interest Payable			$ 15,047
Interest Bearing Promissiory Note [Member]
Loans Payable to Stockholders [Line Items]
Debt Instrument, Face Amount			$ 194,556
Eighteen Month Warrant [Member]
Loans Payable to Stockholders [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights			$ 0.09
Class of Warrant or Right, Number of Securities Called by Warrants or Rights			34,787,162
Five Year Warrant [Member]
Loans Payable to Stockholders [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights			$ 0.1125
Class of Warrant or Right, Number of Securities Called by Warrants or Rights			34,787,162
Interest Bearing Promissory Notes [Member]
Loans Payable to Stockholders [Line Items]
Long-term Debt, Gross			$ 200,000
Loans Payable One [Member]
Loans Payable to Stockholders [Line Items]
Payments of Debt Issuance Costs					$ 31,455
Convertible One-year Promissory Note [Member]
Loans Payable to Stockholders [Line Items]
Debt Instrument, Interest Rate, Effective Percentage							10.00%
Director [Member]
Loans Payable to Stockholders [Line Items]
Proceeds from Related Party Debt			537,148
Summit Resources Inc [Member] | Notes And Warrants 2014 [Member]
Loans Payable to Stockholders [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights		$ 0.50					$ 0.80
Debt Instrument, Face Amount							$ 1,415,000
Repayments of Debt							250,000
Accretion Expense			83,000		$ 7,227		10,950
Due to Related Parties, Current							$ 1,415,000
Debt Conversion, Converted Instrument, Shares Issued		1,080,312
Class of Warrant or Right, Number of Securities Called by Warrants or Rights							1,415,000
Debt Conversion, Original Debt, Amount		$ 165,000
Debt Instrument, Increase, Accrued Interest		$ 105,078
Debt Instrument, Convertible, Conversion Price		$ 0.25
Debt Conversion, Converted Instrument, Warrants or Options Issued		540,156
Due To Officers Or Stock holders Current Net Of Discount						917,000
Due to Officers or Stockholders, Current						$ 1,000,000
Summit Resources Inc [Member] | Maximum [Member] | Notes And Warrants 2014 [Member]
Loans Payable to Stockholders [Line Items]
Long-term Debt, Gross									1,500,000
Summit Resources Inc [Member] | Minimum [Member] | Notes And Warrants 2014 [Member]
Loans Payable to Stockholders [Line Items]
Long-term Debt, Gross									$ 900,000
Stockholders [Member]
Loans Payable to Stockholders [Line Items]
Proceeds from Related Party Debt			$ 3,625,104

Other Current Liabilities (Deta

Other Current Liabilities (Details) - USD ($)	Mar. 31, 2017	Dec. 31, 2016
Payables And Accruals [Line Items]
Accrued expenses	$ 33,358	$ 68,411
Accrued interest	304,266	264,507
Accrued warranties	35,000	45,000
Accrued payroll and benefits	189,322	119,619
Accrued sales tax	0	103
Unearned revenue	55,572	58,407
Other payables and accrued expenses	$ 617,518	$ 556,047

Debt (Details)

Debt (Details) - USD ($)		Mar. 31, 2017	Dec. 31, 2016
Debt Instrument [Line Items]
Debt and Capital Lease Obligations, Total		$ 5,657,578	$ 5,967,129
Less: current portion		(3,798,276)	(4,012,149)
Less: unamortized original issue discount		0	(22,001)
Less: unamortized debt issuance costs		(25,051)	(163,624)
Long-term portion		1,834,251	1,769,355
Unsecured Convertible Debentures [Member]
Debt Instrument [Line Items]
Debt and Capital Lease Obligations, Total		2,114,438	2,114,438
Note Payable To West Virginia Development Office [Member]
Debt Instrument [Line Items]
Debt and Capital Lease Obligations, Total		92,873	92,873
Note Payable To West Virginia Economic Development Authority, Series 1 [Member]
Debt Instrument [Line Items]
Debt and Capital Lease Obligations, Total	[1]	143,312	143,312
Note Payable To West Virginia Infrastructure and Jobs Development Council, Series 1 [Member]
Debt Instrument [Line Items]
Debt and Capital Lease Obligations, Total	[2]	139,229	139,229
Note Payable To West Virginia Economic Development Authority, Series 2 [Member]
Debt Instrument [Line Items]
Debt and Capital Lease Obligations, Total	[1]	572,148	572,148
Note Payable To West Virginia Infrastructure and Jobs Development Council, Series 2 [Member]
Debt Instrument [Line Items]
Debt and Capital Lease Obligations, Total	[2]	581,987	581,987
Note Payable To West Virginia Jobs Investment Trust Board, Series 1 [Member]
Debt Instrument [Line Items]
Debt and Capital Lease Obligations, Total		290,000	290,000
Note Payable To West Virginia Jobs Investment Trust Board, Series 2 [Member]
Debt Instrument [Line Items]
Debt and Capital Lease Obligations, Total		300,000	300,000
Note Payable to West Virginia Economic Development Authority, Series 3 [Member]
Debt Instrument [Line Items]
Debt and Capital Lease Obligations, Total	[1]	168,362	168,362
Capital leases [Member]
Debt Instrument [Line Items]
Debt and Capital Lease Obligations, Total		818,979	928,530
September 10% OID Secured Promissory Note [Member]
Debt Instrument [Line Items]
Debt and Capital Lease Obligations, Total		280,000	480,000
September 2016 20% OID Note [Member]
Debt Instrument [Line Items]
Debt and Capital Lease Obligations, Total		156,250	156,250
Short Term Convertible Notes [Member]
Debt Instrument [Line Items]
Debt and Capital Lease Obligations, Total		$ 0	$ 0
[1]	West Virginia Economic Development Authority
[2]	West Virginia Infrastructure and Jobs Development Council

Debt (Details 1)

Debt (Details 1) - USD ($)	Mar. 31, 2017	Dec. 31, 2016
Schedule of Capitalization, Long-term Debt [Line Items]
2,017	$ 3,733,206
2,018	534,352
2,019	500,357
2,020	495,353
2021 & Thereafter	394,310
Total	$ 5,657,578	$ 5,967,129

Debt (Details Textual)

Debt (Details Textual) - USD ($)	Jan. 07, 2017	Apr. 30, 2012	Mar. 31, 2012	Mar. 31, 2017	Jan. 31, 2017	Mar. 31, 2016
September 2016 10 OID Secured Promissory Note [Member]
Debt Instrument [Line Items]
Debt Instrument, Face Amount				$ 280,000
Notes Payable to West Virginia Development Office [Member]
Debt Instrument [Line Items]
Notes Payable					$ 92,873
Convertible Promissory Note Payable to West Virginia Jobs Investment Trust Board, Series 1 [Member]
Debt Instrument [Line Items]
Duration of Debt Instrument		3 months	18 months
Long-term Debt, Gross (in dollars)			$ 290,000
Debt Instrument, Face Amount				290,000
Convertible Promissory Note Payable to West Virginia Jobs Investment Trust Board, Series 2 [Member]
Debt Instrument [Line Items]
Long-term Debt, Gross (in dollars)		$ 400,000
Debt Instrument, Face Amount				300,000
Capital Leases [Member]
Debt Instrument [Line Items]
Leases Secured Equipment cost				$ 1,783,676
Capital Leases [Member] | Maximum [Member]
Debt Instrument [Line Items]
Imputed Interest Rate				9.45%
Capital Leases [Member] | Minimum [Member]
Debt Instrument [Line Items]
Imputed Interest Rate				5.04%
Convertible Promissory Notes with WVJITB [Member]
Debt Instrument [Line Items]
Debt Instrument, Periodic Payment	$ 50,000
Warrants Not Settleable in Cash, Fair Value Disclosure				$ 7,322		$ 30,825
Debt Conversion, Converted Instrument, Warrants or Options Issued	750,000
Loan Modification Fee	$ 5,000
Common Stock Exercise Price	$ 0.10
Convertible Debentures and September 2016 OID Note [Member]
Debt Instrument [Line Items]
Debt Conversion, Original Debt, Amount				$ 2,384,222
Debt Instrument Original Issue Discount Percentage				20.00%
Debt Instrument, Interest Rate, Effective Percentage				100.00%
Debt Instrument, Debt Default, Amount				$ 2,250,544
Debt Conversion, Description				exchange their debentures for a new 20% OID convertible debenture due September 30, 2017, plus one share of our Common Stock for each $1.00

Common Stock (Details)

Common Stock (Details) - USD ($)		1 Months Ended		3 Months Ended
		Feb. 28, 2017	Jan. 31, 2017	Mar. 31, 2017	Mar. 31, 2016
Class of Stock [Line Items]
Issuance of stock, Shares issued (in shares)		750,000	2,000,000
Issuance of stock, Gross Proceeds (in dollars)				$ 563,508	$ 0
Beginning Balance			$ 16,247	16,247
Issuance of stock for services				230,000
Ending Balance				$ 20,985
Common Stock [Member]
Class of Stock [Line Items]
Balance (in shares)			162,471,373	162,471,373
Issuance of stock, Shares issued (in shares)				3,416,667
Balance (in shares)	[1]			209,848,532
Price Per Share, Beginning Balance (in dollars per share)				Various
Gross Proceeds, Beginning Balance (in dollars)			$ 59,801,216	$ 59,801,216
Gross Proceeds, Ending Balance (in dollars)				60,489,216
Estimated fair value at issuance, Beginning Balance (in dollars)			2,951,293	2,951,293
Estimated fair value at issuance, Ending Balance (in dollars)				5,790,330
Beginning Balance			16,247	16,247
Issuance of stock for services				342
Ending Balance				20,985
Additional Paid in Capital, Beginning Balance (in dollars)			$ 62,440,674	62,440,674
Additional Paid in Capital, Ending Balance (in dollars)				$ 65,839,398
Issuance of stock 1 [Member] | Common Stock [Member]
Class of Stock [Line Items]
Issuance of stock, Shares issued (in shares)	[2]			9,173,330
Issuance of stock, Par Value (in dollars per share)	[2]			$ 0.075
Issuance of stock, Gross Proceeds (in dollars)	[2]			$ 688,000
Issuance of stock, Estimated fair value at issuance (in dollars)	[2]			0
Issuance of stock for services	[2]			917
Issuance of stock, Additional Paid in Capital (in dollars)	[2]			$ 563,508
Issuance of stock 2 [Member] | Common Stock [Member]
Class of Stock [Line Items]
Issuance of stock, Shares issued (in shares)	[3]			3,416,667
Issuance of stock, Price Per Share (in dollars per share)	[3]			various
Issuance of stock, Gross Proceeds (in dollars)	[3]			$ 0
Issuance of stock, Estimated fair value at issuance (in dollars)	[3]			230,000
Issuance of stock for services	[3]			342
Issuance of stock, Additional Paid in Capital (in dollars)	[3]			$ 229,658
Issuance of stock 3 [Member] | Common Stock [Member]
Class of Stock [Line Items]
Issuance of stock, Shares issued (in shares)	[4]			34,787,162
Issuance of stock, Par Value (in dollars per share)	[4]			$ 0.075
Issuance of stock, Gross Proceeds (in dollars)	[4]			$ 0
Issuance of stock, Estimated fair value at issuance (in dollars)	[4]			2,609,037
Issuance of stock for services	[4]			3,479
Issuance of stock, Additional Paid in Capital (in dollars)	[4]			$ 2,605,558
[1]	Includes 21,214,642 shares that contain an anti-dilution provision
[2]	Shares issued in conjunction with the 2016/17 Offering and contains no anti-dilution provisions
[3]	Shares issued in conjunction with certain Consultant Agreements
[4]	Shares issued for conversion of debt and interests. Shares do not contain anti-dilution provisions

Common Stock (Details Textual)

Common Stock (Details Textual) - USD ($)	1 Months Ended				3 Months Ended		12 Months Ended
	Apr. 20, 2017	Feb. 28, 2017	Jan. 31, 2017	Oct. 31, 2016	Mar. 31, 2017	Mar. 31, 2016	Dec. 31, 2016	May 31, 2017	Apr. 25, 2017	Mar. 02, 2017
Class of Stock [Line Items]
Shares Authorized Total								510,000,000
Common Stock, Shares Authorized			750,000,000		500,000,000		500,000,000	500,000,000
Preferred Stock, Shares Authorized					10,000,000		10,000,000	10,000,000
Common Stock, Par or Stated Value Per Share					$ 0.0001		$ 0.0001	$ 0.0001		$ 0.0001
Preferred Stock, Par or Stated Value Per Share					$ 0.0001		$ 0.0001	$ 0.0001
Proceeds from Issuance of Common Stock					$ 563,508	$ 0
Stock Issued During Period, Shares, New Issues				9,173,331	9,173,332
Class of Warrant or Right, Number of Securities Called by Warrants or Rights					18,346,662
Payments of Stock Issuance Costs				$ 88,040
Interest Percentage On Delay Payments				18.00%
Expected Number Of Shares To Be Issued					85,724,996		85,724,996
Debt Instrument, Convertible, Conversion Price					$ 0.075		$ 0.075
Class of Warrant or Right, Outstanding					49,459,532		49,459,532
Stock Issued During Period, Shares, Issued For Services		750,000	2,000,000
Warrant To Purchase Common Stock					25,244,336		25,244,336
Interest Payable					$ 15,047
Shares Issued, Price Per Share				$ 0.075	$ 0.075
Payment for Certain Consultants								$ 50,000
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount					278,374,047	80,102,519
Stock to be Issued upon Execution of Consulting Agreement		500,000
Stockholders' Equity, Reverse Stock Split				1-for-50 reverse stock split
Stockholder Notes One [Member]
Class of Stock [Line Items]
Debt Instrument, Convertible, Conversion Price					$ 0.075
Debt Conversion, Converted Instrument, Shares Issued					34,787,162
Debt Conversion, Converted Instrument, Amount					$ 2,516,719
Interest Payable					$ 92,319
Consulting Agreement [Member]
Class of Stock [Line Items]
Stock Issued During Period, Shares, Issued For Services					1,200,000		250,000
One Time Retainer Payment For Service					$ 10,000
Consulting Agreement [Member] | Issue One [Member]
Class of Stock [Line Items]
Stock Issued During Period, Shares, Issued For Services							250,000
Consulting Agreement [Member] | Issue Two [Member]
Class of Stock [Line Items]
Stock Issued During Period, Shares, Issued For Services							250,000
Consulting Agreement [Member] | Issue Three [Member]
Class of Stock [Line Items]
Stock Issued During Period, Shares, Issued For Services							250,000
Maximum [Member]
Class of Stock [Line Items]
Partial Liquidated Damages Percentage				1.00%
Class B Warrnats [Member]
Class of Stock [Line Items]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights				9,173,331
Class of Warrant or Right, Exercise Price of Warrants or Rights				$ 0.1125
Class A Warrnats [Member]
Class of Stock [Line Items]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights				9,173,331
Class of Warrant or Right, Exercise Price of Warrants or Rights				$ 0.09
Class of Warrant or Right,Exercise Price One [Member] | Stockholder Notes One [Member]
Class of Stock [Line Items]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights					34,787,162
Class of Warrant or Right, Exercise Price of Warrants or Rights					$ 0.09
Term Of Warrants					18 months
Class of Warrant or Right,Exercise Price Two [Member] | Stockholder Notes Two [Member]
Class of Stock [Line Items]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights					34,787,162
Class of Warrant or Right, Exercise Price of Warrants or Rights					$ 0.1125
Term Of Warrants					5 years
Class of Warrant or Right,Exercise Price Three [Member]
Class of Stock [Line Items]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights					666,667
Class of Warrant or Right, Exercise Price of Warrants or Rights					$ 0.09
Class of Warrant or Right,Exercise Price Four [Member]
Class of Stock [Line Items]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights					666,667
Class of Warrant or Right, Exercise Price of Warrants or Rights					$ 0.1125
Investor [Member]
Class of Stock [Line Items]
Proceeds from Issuance of Common Stock					$ 688,000
Number Of Units Sold					68.80
Common Stock [Member]
Class of Stock [Line Items]
Preferred Stock, Shares Authorized					750,000,000					500,000,000
Common Stock, Par or Stated Value Per Share					$ 0.0001
Stock Issued During Period, Shares, New Issues					9,173,330
Stock Issued During Period, Shares, Issued For Services					3,416,667
Common Stock, Conversion Price					$ 0.075
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount					21,214,642
Subsequent Event [Member]
Class of Stock [Line Items]
Shares Authorized Total									760,000,000
Common Stock, Shares Authorized									750,000,000
Preferred Stock, Shares Authorized									10,000,000
Common Stock, Par or Stated Value Per Share									$ 0.0001
Preferred Stock, Par or Stated Value Per Share									$ 0.0001
Debt Instrument, Convertible, Conversion Price	$ 0.075
Debt Conversion, Converted Instrument, Shares Issued	5,000,000
Private Placement Memorandum [Member]
Class of Stock [Line Items]
Sale of Stock, Description of Transaction					the Company is offering, through a placement agent, a maximum of 500 Units of securities at a price of $10,000 per Unit for up to $5,000,000 in gross proceeds (the “Offering”). Each Unit consists of up to (a) 133,333.33 shares of Common Stock, par value $0.0001 (the “Common Stock”), (b) 18 month warrants to purchase 133,333.33 shares of Common Stock at an exercise price of $0.09 per share (the “Class A Warrants”), and (c) five year warrants to purchase 133,333.33 shares of Common Stock at an exercise price of $0.1125 per share (the “Class B Warrants” and together with the Class A Warrants, the “Investor Warrants”). If all 500 Units are sold, the Company will issue an aggregate of 66,666,667 shares of its Common Stock and Investor Warrants to purchase up to 133,333,334 shares of Common Stock. The Offering terminated on March 31, 2017.
Private Placement [Member] | Class B Warrnats [Member]
Class of Stock [Line Items]
Class Of Warrants Or Rights Expiration Term				5 years
Private Placement [Member] | Placement Agent [Member]
Class of Stock [Line Items]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights				2,222,000
Class of Warrant or Right, Exercise Price of Warrants or Rights				$ 0.075

Stock Options and Stock-Based56

Stock Options and Stock-Based Compensation (Details) - Employee Stock Option [Member] - $ / shares	3 Months Ended	12 Months Ended
	Mar. 31, 2017	Dec. 31, 2016
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares, Outstanding	10,780,086
Shares, Granted	560,000
Shares, Exercised	0
Shares, Cancelled or expired	(430,000)
Shares, Outstanding	10,910,086	10,780,086
Shares Exercisable	5,871,656	5,680,899
Weighted average exercise price, Outstanding	$ 0.57
Weighted average exercise price, Granted	0.15
Weighted average exercise price, Exercised	0
Weighted average exercise price, Cancelled or expired	0.48
Weighted average exercise price, Outstanding	0.55	$ 0.57
Weighted average exercise price, Exercisable	$ 0.81	$ 0.84
Weighted ave. remaining contractual life (years), Outstanding	7 years 2 months 12 days	7 years 3 months 18 days
Weighted ave. remaining contractual life (years), Exercisable	5 years 8 months 19 days	5 years 8 months 12 days

Stock Options and Stock-Based57

Stock Options and Stock-Based Compensation (Details 1)	3 Months Ended
	Mar. 31, 2017$ / sharesshares
Exercise Price 0.15 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Exercise Price (in dollars per share) | $ / shares	$ 0.15
Options Outstanding (in shares)	3,560,000
Options Exercisable (in shares)	375,000
Exercise Price 0.25 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Exercise Price (in dollars per share) | $ / shares	$ 0.25
Options Outstanding (in shares)	1,573,336
Options Exercisable (in shares)	839,592
Exercise Price 0.48 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Exercise Price (in dollars per share) | $ / shares	$ 0.48
Options Outstanding (in shares)	150,000
Options Exercisable (in shares)	56,250
Exercise Price 0.50 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Exercise Price (in dollars per share) | $ / shares	$ 0.50
Options Outstanding (in shares)	79,000
Options Exercisable (in shares)	79,000
Exercise Price 0.53 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Exercise Price (in dollars per share) | $ / shares	$ 0.53
Options Outstanding (in shares)	325,000
Options Exercisable (in shares)	142,188
Exercise Price 0.55 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Exercise Price (in dollars per share) | $ / shares	$ 0.55
Options Outstanding (in shares)	3,312,000
Options Exercisable (in shares)	2,468,876
Exercise Price 1.25 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Exercise Price (in dollars per share) | $ / shares	$ 1.25
Options Outstanding (in shares)	50,000
Options Exercisable (in shares)	50,000
Exercise Price 1.50 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Exercise Price (in dollars per share) | $ / shares	$ 1.50
Options Outstanding (in shares)	1,646,000
Options Exercisable (in shares)	1,646,000
Exercise Price 2.00 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Exercise Price (in dollars per share) | $ / shares	$ 2
Options Outstanding (in shares)	214,750
Options Exercisable (in shares)	214,750
Exercise Price 0.15 - 2.00 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Options Outstanding, Exercise Price, Lower Limit (in dollars per share) | $ / shares	$ 0.15
Options Outstanding, Exercise Price, Upper Limit (in dollars per share) | $ / shares	$ 2
Options Outstanding (in shares)	10,910,086
Options Outstanding, Weighted Average Remaining Contractual Life (in years)	7 years 2 months 12 days
Options Outstanding, Weighted Average Exercise Price (in dollars per share) | $ / shares	$ 0.55
Options Exercisable (in shares)	5,871,656
Options Exercisable, Weighted Average Exercise Price (in dollars per share) | $ / shares	$ 0.81

Stock Options and Stock-Based58

Stock Options and Stock-Based Compensation (Details 2)	3 Months Ended
	Mar. 31, 2017$ / sharesshares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares, Non-vested, Beginning Balance | shares	5,340,687
Shares, Granted | shares	560,000
Shares, Forfeited | shares	(279,375)
Shares, Vested | shares	(582,882)
Shares, Non-vested, Ending Balance | shares	5,038,430
Weighted average grant-date fair value, Non-vested, Beginning Balance | $ / shares	$ 0.12
Weighted average grant-date fair value, Granted | $ / shares	0.15
Weighted average grant-date fair value, Forfeited | $ / shares	0.21
Weighted average grant-date fair value, Vested | $ / shares	0.07
Weighted average grant-date fair value, Non-vested, Ending Balance | $ / shares	$ 0.24

Stock Options and Stock-Based59

Stock Options and Stock-Based Compensation (Details 3) - USD ($)	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation expense	$ 41,207	$ 63,800
Selling, General and Administrative Expenses [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation expense	37,822	58,018
Research and Development Expense [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation expense	$ 3,386	$ 5,782

Stock Options and Stock-Based60

Stock Options and Stock-Based Compensation (Details 4)	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted average risk-free interest rate	2.12%	0.00%
Volatility factor	66.32%	0.00%
Weighted average expected life (in years)	7 years	0 years
Dividend rate	0.00%	0.00%

Stock Options and Stock-Based61

Stock Options and Stock-Based Compensation (Details Textual) - USD ($)	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016	Dec. 31, 2012	Dec. 31, 2002
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value	$ 0
Share-based Compensation Arrangement by Share-based Payment Award Estimated Fair Value of Stock Price (in dollars per share)	$ 0.08
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value (in dollars)	$ 41,208	$ 63,800
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value	$ 0.15
Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Weighted Average Expected Term	2 years 6 months 25 days
Share Based Compensation Arrangement By Share Based Payment Award Options Nonvested And Expected To Vest Fair Value	$ 588,548
Common Stock, Capital Shares Reserved for Future Issuance	12,500,000
Equity Incentive Plan 2002 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized (in shares)			4,150,000	450,000
Employee Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value	$ 0.097	$ 0

Warrants (Details)

Warrants (Details) - Warrant [Member] - $ / shares	3 Months Ended		12 Months Ended
	Mar. 31, 2017		Dec. 31, 2016
Class of Warrant or Right [Line Items]
Shares, Outstanding at December 31, 2016	122,475,881
Shares, Granted	92,612,986
Shares, Exercised	0
Shares, Cancelled or expired	(881,899)
Shares, Outstanding at March 31, 2017	214,206,968	[1]	122,475,881
Weighted Average Exercise Price, Outstanding at December, 2016	$ 0.43
Weighted Average Exercise Price, Granted	0.1
Weighted Average Exercise Price, Exercised	0
Weighted Average Exercise Price, Cancelled or expired	1.9
Weighted Average Exercise Price,Shares, Outstanding at March 31, 2017	$ 0.25	[1]	$ 0.43
Weighted Average Remaining Contractual Life (in years), Outstanding	2 years 9 months 22 days	[1]	2 years 1 month 17 days
Weighted Average Remaining Contractual Life (in years), Granted	3 years 9 months 29 days
[1]	includes 57,488,533 warrants that contain an anti-dilution provision

Warrants (Details 1)

Warrants (Details 1) - $ / shares	3 Months Ended		12 Months Ended
	Mar. 31, 2017		Dec. 31, 2016
Class of Warrant or Right [Line Items]
Warrants Outstanding (in shares)	49,459,532		49,459,532
Warrant [Member]
Class of Warrant or Right [Line Items]
Warrants Outstanding (in shares)	214,206,968
Warrants Outstanding, Weighted Average Remaining Contractual Life (in years)	2 years 9 months 22 days	[1]	2 years 1 month 17 days
Warrant Outstanding, Weighted Average Exercise Price (in dollars per share)	$ 0.25	[1]	$ 0.43
Warrant [Member] | Exercise Price 0.075
Class of Warrant or Right [Line Items]
Warrant Outstanding Exercise Price (in dollars per share)	$ 0.075
Warrants Outstanding (in shares)	7,463,720
Warrant [Member] | Exercise Price 0.090
Class of Warrant or Right [Line Items]
Warrant Outstanding Exercise Price (in dollars per share)	$ 0.090
Warrants Outstanding (in shares)	63,592,889
Warrant [Member] | Exercise Price 0.100
Class of Warrant or Right [Line Items]
Warrant Outstanding Exercise Price (in dollars per share)	$ 0.100
Warrants Outstanding (in shares)	1,810,000
Warrant [Member] | Exercise Price 0.110
Class of Warrant or Right [Line Items]
Warrant Outstanding Exercise Price (in dollars per share)	$ 0.110
Warrants Outstanding (in shares)	1,250,000
Warrant [Member] | Exercise Price 0.1125
Class of Warrant or Right [Line Items]
Warrant Outstanding Exercise Price (in dollars per share)	$ 0.1125
Warrants Outstanding (in shares)	63,592,889
Warrant [Member] | Exercise Price 0.190
Class of Warrant or Right [Line Items]
Warrant Outstanding Exercise Price (in dollars per share)	$ 0.190
Warrants Outstanding (in shares)	4,654,145
Warrant [Member] | Exercise Price 0.240
Class of Warrant or Right [Line Items]
Warrant Outstanding Exercise Price (in dollars per share)	$ 0.240
Warrants Outstanding (in shares)	7,500,000
Warrant [Member] | Exercise Price 0.270
Class of Warrant or Right [Line Items]
Warrant Outstanding Exercise Price (in dollars per share)	$ 0.270
Warrants Outstanding (in shares)	14,831,098
Warrant [Member] | Exercise Price 0.280
Class of Warrant or Right [Line Items]
Warrant Outstanding Exercise Price (in dollars per share)	$ 0.280
Warrants Outstanding (in shares)	2,845,000
Warrant [Member] | Exercise Price 0.325
Class of Warrant or Right [Line Items]
Warrant Outstanding Exercise Price (in dollars per share)	$ 0.325
Warrants Outstanding (in shares)	8,029,001
Warrant [Member] | Exercise Price 0.375
Class of Warrant or Right [Line Items]
Warrant Outstanding Exercise Price (in dollars per share)	$ 0.375
Warrants Outstanding (in shares)	741,000
Warrant [Member] | Exercise Price 0.400
Class of Warrant or Right [Line Items]
Warrant Outstanding Exercise Price (in dollars per share)	$ 0.400
Warrants Outstanding (in shares)	1,040,000
Warrant [Member] | Exercise Price 0.450
Class of Warrant or Right [Line Items]
Warrant Outstanding Exercise Price (in dollars per share)	$ 0.450
Warrants Outstanding (in shares)	1,730,000
Warrant [Member] | Exercise Price 0.500
Class of Warrant or Right [Line Items]
Warrant Outstanding Exercise Price (in dollars per share)	$ 0.500
Warrants Outstanding (in shares)	13,315,667
Warrant [Member] | Exercise Price 0.740
Class of Warrant or Right [Line Items]
Warrant Outstanding Exercise Price (in dollars per share)	$ 0.740
Warrants Outstanding (in shares)	7,309,395
Warrant [Member] | Exercise Price 0.750
Class of Warrant or Right [Line Items]
Warrant Outstanding Exercise Price (in dollars per share)	$ 0.750
Warrants Outstanding (in shares)	491,250
Warrant [Member] | Exercise Price 0.800
Class of Warrant or Right [Line Items]
Warrant Outstanding Exercise Price (in dollars per share)	$ 0.800
Warrants Outstanding (in shares)	1,415,000
Warrant [Member] | Exercise Price 1.100
Class of Warrant or Right [Line Items]
Warrant Outstanding Exercise Price (in dollars per share)	$ 1.100
Warrants Outstanding (in shares)	11,773,275
Warrant [Member] | Exercise Price 1.120
Class of Warrant or Right [Line Items]
Warrant Outstanding Exercise Price (in dollars per share)	$ 1.120
Warrants Outstanding (in shares)	263,750
Warrant [Member] | Exercise Price 2.200
Class of Warrant or Right [Line Items]
Warrant Outstanding Exercise Price (in dollars per share)	$ 2.200
Warrants Outstanding (in shares)	70,000
Warrant [Member] | Exercise Price 0.25
Class of Warrant or Right [Line Items]
Warrant Outstanding Exercise Price (in dollars per share)	$ 2.250
Warrants Outstanding (in shares)	488,889
Warrant [Member] | Exercise Price 0.075-2.25
Class of Warrant or Right [Line Items]
Warrants Outstanding (in shares)	214,206,968
Warrants Outstanding, Weighted Average Remaining Contractual Life (in years)	2 years 9 months 22 days
Warrant Outstanding, Weighted Average Exercise Price (in dollars per share)	$ 0.25
Warrant [Member] | Exercise Price 0.075-2.25 | Maximum [Member]
Class of Warrant or Right [Line Items]
Warrant Outstanding Exercise Price (in dollars per share)	2.250
Warrant [Member] | Exercise Price 0.075-2.25 | Minimum [Member]
Class of Warrant or Right [Line Items]
Warrant Outstanding Exercise Price (in dollars per share)	$ 0.075
[1]	includes 57,488,533 warrants that contain an anti-dilution provision

Warrants (Details Textual)

Warrants (Details Textual) - USD ($)	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016	May 31, 2017	Dec. 31, 2016
Class of Warrant or Right [Line Items]
Warrants Outstanding (in shares)	49,459,532			49,459,532
Interest Expense, Other	$ 150,158
Class of Warrant or Right, Number of Securities Called by Warrants or Rights	18,346,662
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	278,374,047	80,102,519
Unsecured Convertible Debentures [Member]
Class of Warrant or Right [Line Items]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights	2,222,000
Convertible Notes Payable [Member]
Class of Warrant or Right [Line Items]
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right	69,574,324
Investor [Member]
Class of Warrant or Right [Line Items]
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right			18,346,662
Consultant [Member]
Class of Warrant or Right [Line Items]
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right			1,720,000
Convertible Promissory Note Payable To West Virginia Jobs Investment Trust Board, Series 1 [Member]
Class of Warrant or Right [Line Items]
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right			750,000
Warrant [Member]
Class of Warrant or Right [Line Items]
Warrants Outstanding (in shares)	214,206,968
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	57,488,533

Commitments and Contingencies (

Commitments and Contingencies (Details Textual) - USD ($)	1 Months Ended	2 Months Ended	3 Months Ended
	Dec. 31, 2016	Apr. 01, 2017	Mar. 31, 2017	Mar. 31, 2016	Jan. 31, 2017	May 31, 2016
Loss Contingencies [Line Items]
Accrued warranties	$ 45,000		$ 35,000
Loss Contingency, Estimate of Possible Loss	213,032
MPR [Member]
Loss Contingencies [Line Items]
Loss Contingency, Estimate of Possible Loss					$ 37,000
Litigation Settlement, Amount	161,889
Settlement Liabilities, Current					$ 111,889.16
First Payment [Member] | MPR [Member]
Loss Contingencies [Line Items]
Payments for Legal Settlements	25,000
George Washington University [Member]
Loss Contingencies [Line Items]
Royalty Expenses			699	$ 1,257
Accrued Royalties, Current			0
Accounts Payable, Current			47,700
Royalties and Interest Expenses			$ 110,374
LAESI Instruments [Member]
Loss Contingencies [Line Items]
Accrued warranties	$ 45,000
Yale University [Member]
Loss Contingencies [Line Items]
Reduce Royalties Percentage After Net Sales of Licensed Products		2.50%
Accrued Royalty						$ 5,000
Yale University [Member] | Subsequent Event [Member]
Loss Contingencies [Line Items]
Minimum Royalties Year One		$ 10,000
Minimum Royalties Year Two		15,000
Minimum Royalties Year Three		20,000
Licence Maintenance Royalty Expenses		2,500
Licence Maintenance Royalty Expenses, After Current Year		5,000
Royalty Pay On First Sale Of Licence Product		5,000
Royalty On Approval For Commercial Sale With a Government Regulatory		7,500
Royalty On First Sale On Approval With a Government Regulatory		10,000
Minimum Royalty Year Four		30,000
Minimum Royalty Year Five		40,000
Minimum Royalty Year Six		$ 50,000

Supplemental Cash Flow Inform66

Supplemental Cash Flow Information (Details) - USD ($)	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Equipment acquired under capital leases	$ 0	$ 18,344
Issuance of common stock upon conversion of accrued interest	0	41,393
Issuance of common stock upon conversion of related party debt and interest	2,614,037	0
Issuance costs for short-term debt	0	5,000
Fair value of warrant committed to placement agent	$ 0	$ 2,456

Supplemental Cash Flow Inform67

Supplemental Cash Flow Information (Details Textual) - USD ($)	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Interest Paid	$ 104,566	$ 47,459

Evaluation of Subsequent Even68

Evaluation of Subsequent Events (Details Textual) - USD ($)	Apr. 07, 2017	Mar. 14, 2017	Apr. 30, 2017	Apr. 20, 2017	Feb. 28, 2017	Jan. 31, 2017	Mar. 31, 2017	Mar. 31, 2016	Jul. 31, 2017	Apr. 21, 2017	Dec. 31, 2016
Subsequent Event [Line Items]
Proceeds from Related Party Debt		$ 255,000
Stock Issued During Period, Shares, Issued For Services					750,000	2,000,000
Debt Instrument, Convertible, Conversion Price							$ 0.075				$ 0.075
Payments To Acquire Machinery and Equipment							$ 19,890	$ 0
Repayments of Debt							200,000	7,783
Proceeds from Sale of Equity Method Investments							$ 0	$ 637,100
AzurRx BioPharma Inc [Member]
Subsequent Event [Line Items]
Sale of Stock, Number of Shares Issued in Transaction							125,757
Equity Method Investment, Ownership Percentage							1.70%
Convertible Note [Member]
Subsequent Event [Line Items]
Debt Instrument, Convertible, Threshold Percentage of Stock Price Trigger							85.00%
Debt Conversion, Converted Instrument, Expiration or Due Date							Sep. 30, 2017
Debt Conversion, Converted Instrument, Amount							$ 308,439
Subsequent Event [Member]
Subsequent Event [Line Items]
Proceeds from Related Party Debt			$ 415,000
Debt Instrument, Convertible, Conversion Price				$ 0.075
Debt Conversion, Converted Instrument, Shares Issued				5,000,000
Debt Instrument, Face Amount	$ 1,750,000
Debt Conversion, Original Debt, Amount				$ 375,000
Repayments of Debt				375,000
Convertible Debt				$ 301,577.79
Subsequent Event [Member] | AzurRx BioPharma Inc [Member]
Subsequent Event [Line Items]
Sale of Stock, Number of Shares Issued in Transaction			25,000
Equity Method Investment, Shares in Number			100,757
Proceeds from Sale of Equity Method Investments			$ 85,355
Equity Method Investment, Ownership Percentage			1.36%
Subsequent Event [Member] | Senior Secured Convertible Note [Member]
Subsequent Event [Line Items]
Proceeds from Related Party Debt	300,000								$ 1,250,000
Debt Instrument, Periodic Payment, Principal	$ 62,030.86
Warrants Expiration Terms	36 months
Debt Instrument, Convertible, Conversion Price	$ 0.075
Debt Instrument, Face Amount	$ 1,750,000
Debt Instrument, Term	36 months
Percentage of Equity Proceeds Agreed to Prepay the Loan	30.00%
Related Party Debt, Prepayments of Loan by Equity Offering	$ 500,000
Related Party Debt Mandatory Prepayment, Equity Offering Limit	5,000,000
Payments To Acquire Machinery and Equipment	$ 1,250,000
Debt Instrument, Interest Rate Terms	interest at the rate of 15% per annum), or (b) 20% of the cash proceeds we receive from customers who request services from the Company using the new mass spectrometer equipment
Debt Instrument, Convertible, Threshold Percentage of Stock Price Trigger	85.00%
Convertible Debt										$ 301,577.79
Subsequent Event [Member] | September 2016 Oid Secured Promissory Note [Member]
Subsequent Event [Line Items]
Convertible Debt										$ 301,577.79
Subsequent Event [Member] | Consulting Agreement [Member]
Subsequent Event [Line Items]
Stock Issued During Period, Shares, Issued For Services			250,000